

**Session Title:** #326: How to Navigate the Annual Meeting (Fellows & Junior Faculty ONLY)

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S501

**Time:** 7:30 AM - 8:00 AM

- How to Navigate the Annual Meeting (Fellows & Junior Faculty ONLY)

*John E. Pippen, MD, FACP*

**Session Title:** #19: Cancer Fatigue and Contributing Factors: Recognition and Treatment

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E354b

**Time:** 8:00 AM - 9:15 AM

- Cancer-Related Fatigue: Who Gets It and How Long Does It Last?

*Ann Malone Berger, RN, PhD, AOCN, FAAN*

- Do Medications Work to Decrease Cancer-Related Fatigue?

*Eduardo Bruera, MD*

- Non Pharmacologic Interventions to Decrease Fatigue

*Bernadine Cimprich, RN, PhD, CS, FAAN*

**Session Title:** #24: Clinical Trials in Survivorship Populations: Emerging Concepts and Barriers to Application

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S100a

**Time:** 8:00 AM - 9:15 AM

- Promoting Health During and Beyond Cancer Therapy

*Melissa M. Hudson, MD*

- Conducting Clinical Trials of Physical Activity in Cancer Survivors  
*Melinda L. Irwin, PhD, MPH*
  - Clinical Trials in Cancer Survivors with Chemotherapy-related Cognitive Impairment  
*Janette L. Vardy, MD, PhD*
- 

**Session Title:** #35: Curable and Highly Treatable Leukemias: How Do I Optimize Outcome?

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E354a

**Time:** 8:00 AM - 9:15 AM

- Update on acute promyelocytic leukemia  
*Bayard L. Powell, MD*
  - Monitoring recommendations. What defines resistance?  
*Giuseppe Saglio, MD*
  - Therapy for CML. What is the best TKI? When? And beyond?  
*Moshe Talpaz, MD*
- 

**Session Title:** #48: The Expanding Role of Antibody-based Therapy in Children, Adolescents, and Young Adults with Cancer

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S504

**Time:** 8:00 AM - 9:15 AM

- Progress in treatment of high-risk neuroblastoma with immunotherapy  
*Alice L. Yu, MD, PhD*
- Update on Immunotherapy Strategies in the Treatment of Lymphomas in children, adolescents and young adults  
*Mitchell S. Cairo, MD*
- The efficacy of epitope-specific IGFR1 antibodies in therapy of pediatric, adolescent and young adult solid tumors  
*Douglas Yee, MD*

**Session Title:** #55: How to Use Data to Improve Practice: Nexus of Quality and Efficiency

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E353

**Time:** 8:00 AM - 9:15 AM

- Getting More out of QOPI  
*Robert D. Siegel, MD*
- Challenge of reducing disease specific variation in care.  
*Peter G. Ellis, MD*
- Quality and Efficiency - Continuous Improvement Tools for the Oncology Practice  
*David C. Fryefield, MD*

**Session Title:** #71: Melanoma Immunotherapy: Current Status, Future Opportunities

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S406 (Vista Room)

**Time:** 8:00 AM - 9:15 AM

- Adoptive T Cell transfer  
*Patrick Hwu, MD*
- Checkpoint blockade  
*Jedd D. Wolchok, MD, PhD*
- Melanoma vaccines  
*Craig L. Slingluff, MD*

**Session Title:** #72: Micronutrient Supplementation versus Dietary Modification of Cancer Prevention: Which Is Better?

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S100b

**Time:** 8:00 AM - 9:15 AM

- Epidemiology versus clinical trials as evidence for propensity of dietary components/micronutrients to prevent cancer

*Peter Gann, MD, ScD*

- Vitamin D: should we be supplementing to prevent cancer?

*John A Milner, PhD*

---

**Session Title:** #103: Therapeutic Options for Patients with Breast Cancer with a Family History or BRCA Mutation

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E Arie Crown Theater

**Time:** 8:00 AM - 9:15 AM

- Surgical options for breast cancer patients with a BRCA 1/2 mutation or a familial predisposition

*Marian B.E. Menke-Pluymers, MD, PhD*

- Radiation therapy and hereditary breast cancer

*Abram Recht, MD*

- Systemic therapy in BRCA1 and BRCA2 mutation carriers with breast cancer

*Susan M. Domchek, MD*

---

**Session Title:** #142: When Onco-cardiology Meets Cardio-oncology: A Global Perspective

**Session Type:** Clinical Problems in Oncology Session

**Date:** Saturday, June 5

**Location:** E451a

**Time:** 8:00 AM - 9:15 AM

- Patterns of cardiac toxicity with novel therapies and management issues

*Erica L. Mayer, MD*

- Pathophysiology of cardiotoxicity in chemotherapy and targeted therapy

*Daniel John Lenihan, MD*

- Cardiac problems in oncology patients beyond cardiotoxicity - a road to cancer cachexia

*Stefan D Anker, MD, PhD*

**Session Title:** #172: Breast Cancer - Metastatic

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** E450b

**Time:** 8:00 AM - 12:00 PM

- Breast Cancer - Metastatic

*Anne F. Schott, MD*

- Breast Cancer - Metastatic

*Hope S. Rugo, MD*

1 #1012-A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).

*Kathy Miller, MD*

2 #1013- Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.

*Florence Dalenc*

3 #1014-Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.

*Phuong Khanh H. Morrow*

4 #1015-Correlation of cyclin D1, A870G, polymorphism and clinical outcome in patients with HER2-positive, metastatic breast cancer treated with lapatinib plus capecitabine.

*Melissa Janae Labonte*

5 #1016-Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.

*Patricia LoRusso, DO*

- Discussion

*David A. Cameron, MD*

7 #1018-Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.

*Rebecca Alexandra Dent*

9 #1020-Activity of taxane chemotherapy for metastatic breast cancer (MBC) in BRCA1 and BRCA2 mutation carriers compared to sporadic BC patients.

*Caroline Seynaeve*

10 #1021-Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).

*Adam Brufsky*

- Discussion

*Lisa A. Carey, MD*

11 #1022-A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study.

*Elke Jaeger*

12 #1023-Impact of first-line chemotherapy duration in metastatic breast cancer: A systematic review.

*Alessandra Gennari*

13 #1024-Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial.

*Alison Stopeck*

14 #1025-Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: Results from a randomized phase III trial.

*Lesley Fallowfield*

15 #1026-Ibandronate in the treatment of patients (pts) with breast cancer (BC) with metastatic bone disease (MBD): Final results of a large-scale noninterventional study (NIS).

*Ingo J. Diel*

- Discussion

*Catherine H. Van Poznak, MD*

16 #1027-The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases.

*Carey K. Anders*

17 #1028-A graded prognostic assessment (GPA) for women with breast cancer and brain metastases.

*Paul W. Sperduto*

18 #1029-Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.

*Anna Niwinska, MD, PhD*

19 #1030-Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy.

*Renata Duchnowska*

- Discussion

*Nancy U. Lin, MD*

20 #1031-Male breast cancer in veteran population: Retrospective analysis of VACCR database.

*Shanmuga Subbiah, MD, MBBS*

---

**Session Title:** #174: Central Nervous System Tumors

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S103

**Time:** 8:00 AM - 12:00 PM

- Central Nervous System Tumors

*David Peereboom, MD*

- Central Nervous System Tumors

*Deric M. Park, MD*

1 #2009-ANG1005: Results of a phase I study in patients with recurrent malignant glioma.

*Jan Drappatz*

2 #2010-Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study.

*Karen Fink*

3 #2011-Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM).

*David Schiff, MD*

4 #2012-Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma.

*Jaishri O'Neill Blakeley*

- Discussion

*John L. Villano, MD, PhD*

5 #2013-Isotrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: A NABTT CNS consortium study.

*Stuart Grossman, MD*

6 #2014-Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).

*Rose Lai*

7 #2015-The efficacy of interferon- $\beta$  and temozolomide combination therapy for newly diagnosed primary glioblastoma: Multicenter study.

*Kazuya Motomura*

8 #2016-Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D.

*Jann Nagina Sarkaria*

9 #2017-Testosterone levels in men undergoing treatment for malignant gliomas.

*Matthias Holdhoff*

- Discussion

*Martin Kelly Nicholas, MD, PhD*

10 #2018-NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

*Evanthia Galanis, MD*

11 #2019-Heterogeneity of response to bevacizumab in multifocal and multicentric glioblastomas.

*Shirley S. Ong*

12 #2020-Change in pattern of relapse in newly diagnosed high-grade glioma following bevacizumab therapy.

*Michael L. Gruber*

13 #2021-Radiographic patterns of relapse in glioblastoma.

*Marc C. Chamberlain, MD*

14 #2022-Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenic drugs?

*Enrico Franceschi, MD*

15 #2023-Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).

*James J. Vredenburgh*

16 #2024-Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab.

*Jing Wu*

17 #2025-Deletion of NFKBIA in malignant gliomas.

*Markus Bredel*

18 #2026-Use of perfusion MR imaging for differentiation between tumor progression and pseudo-progression in recurrent glioblastoma multiforme.

*Christel Heidemans-Hazelaar*

19 #2027-Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients treated with concomitant chemoradiation: A prospective study.

*Philippe Metellus*

20 #2028-CD133 expression in glioblastoma recurring after radiation therapy.

*Tonia Cenci*

21 #2029-Prognostic value and analytical performance (reproducibility) of Ki67 index in anaplastic oligodendroglial tumors: A translational study of the EORTC Brain Tumor Group.

*Matthias Preusser*

22 #2030-Stereotactic radiosurgery: A new paradigm for melanoma and renal cell carcinoma spine metastases.

*Anu Thiagaragan, MD*

23 #2031-Chemotherapy (CT) alone for epidural spinal cord compression (ESCC) from germ cell tumors (GCT).

*Christian Grommes*

24 #2032-Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST).

*Lakshmi Nayak*

- Discussion

*Eric L. Chang, MD*

**Session Title:** #175: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** E450a

**Time:** 8:00 AM - 12:00 PM

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

*Lesley Seymour, MD, PhD*

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

*Razelle Kurzrock, MD*

1 #2515-Phase I trials of novel molecularly targeted therapies: Should we pay more attention to toxicities occurring after cycle 1?

*Sophie Postel-Vinay*

2 #2516-Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience.

*Dionysios Papadatos-Pastos, MD, MRCP*

3 #2517-An international pooled analysis identifying predictive factors associated with toxicities in phase I trials (Delphi).

*Carlos Alberto Gomez-Roca*

4 #2518-Multi-institutional prognostic factor analysis of patients (pts) enrolled in phase I (Ph I) oncology trials: Can pts selection be improved?

*David Olmos*

5 #2519-Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience.

*Salma M. Alam*

6 #2520-VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints.

*Manish Sharma*

- Discussion

*David J Stewart*

7 #2521-The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population).

*Michael Jäger*

8 #2522-Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC).

*Ben Markman*

9 #2523-Radioimmunotherapy (RIT) with 131I-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial.

*Gianluca Del Conte*

10 #2524-First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiotensin 2.

*Lee S. Rosen*

11 #2525-Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

*Amita Patnaik*

- Discussion

*Ravi Salgia, MD, PhD*

12 #2526-Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.

*Michael J. Pishvaian*

13 #2527-Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium trial.

*Timothy W. Synold, PharmD*

14 #2528-AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.

*Thomas A. Samuel, MD*

15 #2529-A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.

*Jonathan Wade Goldman*

16 #2530-Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors.

*Craig Peter Carden*

17 #2531-Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

*T.R. Jeffry Evans*

- Discussion

*Lesley Seymour, MD, PhD*

18 #2532-Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy.

*James L. Rubenstein*

19 #2533-A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC).

*Syma Iqbal*

20 #2534-A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P).

*Maysa M. Abu-Khalaf, MD*

21 #2535-A phase I study of gemcitabine, capecitabine, and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies.

*Sujatha Nallapareddy*

22 #2536-A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.

*Carol A. Townsley*

23 #2537-Targeted cancer therapies: FDA approval overview.

*Patricia Cortazar*

24 #2538-Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.

*John S. Kauh, MD*

- Discussion

*Razelle Kurzrock, MD*

**Session Title:** #183: Health Services Research

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S403

**Time:** 8:00 AM - 12:00 PM

- Health Services Research

*Benjamin D. Smith, MD*

- Health Services Research

*Elissa Ozanne, PhD*

1 #6009-Burden of illness estimates of metastatic breast cancer (MBC) in the United States.

*Sonja Sorensen*

2 #6010-Adjuvant endocrine monotherapy with tamoxifen or aromatase inhibitors for postmenopausal women with breast cancer: What is the economic impact of CYP 2D6 testing?

*Tallal Younis*

3 #6011-Comparative effectiveness of screening, surgery, and chemoprevention among BRCA1/2 mutation carriers.

*Victor Grann, MD, MPH*

4 #6012-Therapeutic options for low-risk prostate cancer: A cost-effectiveness analysis.

*Julia H Hayes*

5 #6013-Year one evaluation of regional pay for quality (P4Q) oncology program.

*Jeffrey A. Scott*

6 #6014-Conflicts of interest in economic analyses presented at the American Society of Clinical Oncology Annual Meeting.

*Sekwon Jang*

7 #6015-Does increasing insurance improve outcomes for U.S. cancer patients?

*Jillian K Smith*

- Discussion: Role of cost and comparative effectiveness research in guiding health policy

*Elena B. Elkin, PhD*

8 #6016-Surgeon influence on patient appraisal of ASCO breast cancer quality indicators.

*Sarah T. Hawley, MD, PhD*

9 #6017-The impact of audit and feedback on nodal harvest in colorectal cancer (CRC).

*Geoffrey A. Porter*

10 #6018-Quality of care in non-small cell lung cancer (NSCLC): Findings from the Florida initiative for quality cancer care (FIQCC).

*Tawee Tanvetyanon*

11 #6019-Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma: Evaluating community guideline adherence.

*Nader N Massarweh, MD*

12 #6020-Scientific evidence underlying National Comprehensive Cancer Network Clinical Practice Guidelines.

*Thejaswi K.Poonacha*

- Discussion: Oncology guidelines: adherence and appraisal

*Jennifer Malin*

13 #6021-End of life care for elderly patients with advanced lung cancer in the United States and Ontario.

*K. Robin Yabroff*

14 #6022-Impact of care at NCI-designated Comprehensive Cancer Centers (NCICCCs) on racial differences in prostate cancer-specific survival.

*Can-Lan Sun*

15 #6023-Trends in prostatectomy: Centralization, robotics, and access to care.

*Karyn Beth Stitzenberg*

16 #6024-PSA surveillance in men with localized prostate cancer.

*Debra Nana Yeboa*

17 #6025-Restoration of medical oncology services at Charity Hospital in New Orleans after Hurricane Katrina: A 2-year experience of the Louisiana State University Health Sciences Center (LSUHSC).

*Brian C. Boulmay, MD*

18 #6026-Appropriateness of cardiovascular (CV) care in cancer survivors (CS).

*Winson Y. Cheung*

19 #6027-Estimation of the U.S. rate of neutropenic complications for cancer hospital discharges.

*Mike Dickson*

- Discussion: Patterns of cancer care

*Stephen B. Edge, MD*

20 #6028-Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs).

*Bostjan Seruga*

21 #6029-A compendium of unpublished phase III clinical trials in oncology: Characteristics and impact on clinical practice.

*Vincent Channing Tam, MD, FRCPC*

22 #6030-The assessment of cost and other barriers to patient clinical trial participation in the community setting.

*Douglas Weckstein*

23 #6031-Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.

*Benoit You*

24 #6032-Influence of nonclinical patient factors on decisions to recommend breast cancer adjuvant chemotherapy.

*Tunghi May Pini, MD, MPH*

25 #6033-Factors associated with decision making for use of adjuvant chemotherapy (AT) in referred patients (pts) with resected high-risk colon cancer (CC).

*Doran Ksienski*

- Discussion: Clinical trials and decision making

*Benjamin Djulbegovic, MD, PhD*

---

**Session Title:** #195: Cancer Prevention/Epidemiology

**Session Type:** General Poster Session

**Date:** Saturday, June 5

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

1A #1534-High prevalence of *BRCA1/2* germline mutations in female breast cancer patients with triple-negative phenotype (TNBC) and family history.

*Cristina Saura*

1B #1535-Prospective screening for Lynch syndrome (LS) in a cohort of colorectal cancer (CRC) surgical patients in a community hospital.

*Paul R. Duncan*

1C #1536-Effect of *BRCA1* gene and estrogen-receptor  $\alpha$ ; on regulation of serum estradiol levels in women with breast cancer.

*Ja Yeon Kim*

1D #1537-Association of death receptor 4 variant (Glu228Ala) with ovarian cancer risk in *BRCA1*-mutation carriers.

*Michelle G Dick*

1E #1538-Breast cancer gene expression profile in young women who are noncarriers of *BRCA1/2* mutations with and without familial history.

*Dirce Maria Carraro 1*

1F #1539-Publication bias in translational research and number of polymorphisms analyzed in genetic association studies.

*Lampriani Tsali*

1G #1540-MUTYH gene mutations in Spanish individuals with multiple colorectal adenomas without *APC* gene mutation.

*Ana Isabel Ferrer*

1H #1541-Association between *XRCC1* gene haplotype tagging single nucleotide polymorphisms and non-small cell lung cancer in Korean patients.

*Gyeong-won Lee*

2A #1542-Mutation position in *BRCA*-associated breast cancers.

*Funda Meric-Bernstam*

2B #1543-Association of HER2 655 ile&rarr;Val polymorphism with pathological response to neoadjuvant chemotherapy and trastuzumab in breast cancer.

*Alma M. Astorga*

2C #1544-Is lobular breast cancer mainly inherited from the father?

*Hakan Lars Olsson*

2D #1545-Gene expression profiles in non-small cell lung cancers (NSCLCs) and in corresponding healthy lung tissues in smokers versus nonsmokers.

*Amelia Szymanowska-Narloch*

2E #1546-Pilot program of fast-track germline genetic analyses as part of integrated breast, ovarian, or gastrointestinal personalized cancer care program.

*Olivier Caron*

2F #1547-Disparities in referral by risk profile for genetic counseling of high-risk individuals: A disease-specific analysis of mutation frequencies of 1,193 patients presenting for presumptive hereditary breast ovarian cancer (HBOC) or colorectal cancer syndromes (CCS).

*Iuliana Shapira*

2G #1548-Characterization of a major colon cancer susceptibility locus (Ccs3) on mouse chromosome 3.

*Charles Meunier*

2H #1549-Analysis of plasma proteome from BRCA1/BRCA2 mutation carriers as modifier risk factor of breast cancer.

*Ana Custodio*

3A #1550-A unique community-based family cancer registry.

*Nashat Y. Gabrail*

3B #1551-Promoter methylation of p16INK4A, RASSF1A, and RAR2b genes in tumor DNA from patients with breast cancer (BC) in correlation with clinical recurrence.

*Soultana Voyatzi, BSc*

3C #1552-Type II diabetes and breast cancer.

*Kirsten D Erickson*

3D #1553-Does dietary estrogen intake from meat relate to the incidence of hormone-dependent cancers?

*Yasushi Handa, MD, PhD*

3E #1554-A multi-analyte serum test for the early diagnosis of non-small cell lung cancer.

*Michael S. Vercillo*

3F #1555-Lung cancer risk and polymorphisms in UGT1A6.

*Ley-Fang Kua*

3G #1556-Breast density and calculated breast cancer risk.

*Farrah B. Khan*

3H #1557-Method of detection of DCIS to predict HER2 overexpression.

*Simone Schrading*

4C #1560-The accuracy of the HPV-associated diseases risk assessment inventory for detecting cervical dysplasias in medically underserved women in the United States.

*Mfon Samuel Cyrus-David*

4D #1561-Economic value of disability adjusted life years lost to cancers: 2008.

*Rijo M John*

4E #1562-The association between the use of statin and breast cancer recurrence.

*Young Kwang Chae*

4F #1563-A prospective study of combined colon and endometrial cancer screening in women with Lynch syndrome: A novel patient-centered approach.

*Marilyn Huang*

4G #1564-Factors influencing long-term altered quality of life, sexual functioning, and menopausal symptoms after prophylactic bilateral salpingo-oophorectomy (PBSO) among high-risk women (wm).

*Cyril Touboul*

4H #1565-Influence of thiozolidinediones (TZD) exposure on the progression of oral leukoplakia (L) and erythroplakia (E) to the development of head and neck cancer (HNC).

*Anuradha Kunthur*

5B #1567-High-precision tissue acquisition in the evaluation of breast microcalcifications.

*Jaak Janssens*

5C #1568-Barriers to colorectal cancer screening among African American population.

*Zaw Min Bo*

5D #1569-Determinants of low cell yield in random fine needle aspiration (rFNA) procedures of the breast in healthy women unselected by risk.

*Seema Ahsan Khan, MD, FACS, MPH*

5E #1570-Knowledge of cancer risk factors.

*Karen Maxwell Gil*

5F #1571-Mammography utilization in women age 40 to 49: The French EDIFICE survey.

*François Eisinger*

5G #1572-Young age at first live birth and long duration of breast feeding: Are they universally accepted protective factors against breast cancer? A case control study of the cancer research group in Pakistan.

*Misbah Masood*

5H #1573-Do Asian breast cancer patients younger than age 40 have more aggressive biologic characteristics than their western counterparts? A comparison between Shanghai and Vienna.

*Muy-Kheng Maria Tea, MD*

6A #1574-Fecundity after childhood cancer: A nationwide, population-based study.

*Milada Cvancarova*

6B #1575-Trends in incidence and location of colorectal cancer in the colonoscopy era.

*Dianne Pulte*

6C #1576-Predictors of independent living status in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

*Alicia Kunin-Batson*

6D #1577-Differing age patterns in chronic myeloid leukemia by racial ethnic group.

*Adam M Mendizabal*

6E #1578-Characterization of 25-OH vitamin D (Vit D) and factors associated with obesity in patients with high-risk breast cancer (BC): NCIC CTG MA.21.

*Elena V Tsvetkova, MD*

6F #1579-Risk of metachronous contralateral testicular germ cell tumor (met-TGCT) among 7,248 Norwegian patients (1953-2007).

*Kristine Engen Andreassen*

6G #1580-The effect of age on delay in diagnosis and stage of breast cancer.

*Ann H. Partridge, MD*

6H #1581-Innate immunity-related sequence variants as predictors of breast cancer risk among women of African descent.

*Kevin Sean Kimbro*

7A #1582-Is tumor size important in HER2-positive breast cancer?

*Carol Parise*

7B #1583-Incidence of early-onset multiple myeloma among families with endometrial carcinoma.

*Ashwin R. Sama, MD*

7C #1584-Breast cancer and high-risk diagnosis in core biopsies stratified by ethnicity.

*Elizabeth Min Hui Kim*

7D #1585-Epidemiologic risk factors associated with breast cancer subtypes.

*Arvind Bambhroliya*

7E #1586-The influence of ER on small HER2-positive invasive breast cancers.

*Vincent Caggiano*

7F #1587-Frequency of L858R and D746-750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by mutation-specific antibodies.

*Anastasios T. Dimou*

7G #1588-A significant dietary change after breast cancer diagnosis: Early results of a United Kingdom prospective multicenter study.

*Louiza Sofia Velentzis*

7H #1589-Pathologic features and outcomes of pregnancy-associated breast cancer (PABC): A case control study.

*Conleth Murphy*

8A #1590-Mortality for non-AIDS-defining cancers among people with AIDS.

*Antonella Zucchetto*

8B #1591-Clinical and pathologic characteristics of Hispanic breast cancer patients in a tertiary care safety net hospital.

*Theresa Marguerite Lee, MD*

8C #1592-Patterns of antidepressant use among women initiating tamoxifen therapy for the treatment of breast cancer in Ontario, Canada.

*Catherine M Kelly, MRCP, MSc*

8D #1593-Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter?

*Shirin Muhsen*

8E #1594-Longitudinal self-reported and serum-based assessment of tobacco or nicotine use in head and neck cancer patients during definitive radiotherapy or chemoradiotherapy.

*Mahesh R. Kudrimoti*

8F #1595-Survival among never and ever smokers with lung cancer in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study.

*Christelle Clément-Duchêne*

8G #1596-Characteristics and behavior of invasive breast cancer developed despite prior oophorectomy.

*James Ryan Nitzkowski*

8H #1597-Incidental finding of pulmonary nodule on CT pulmonary angiogram (CTPA) in view of current surveillance recommendations: Is any lung cancer screening protocol applicable?

*Orlando C Enrizo, MD*

9A #1598-Prevalence of anal squamous intraepithelial lesions in HIV-positive and HIV-negative men who have sex with men in Thailand.

*Thep Chalermchai*

9B #1599-Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer.

*Jaine K Blayney*

9C #1600-Recurrence pattern in early-stage breast cancer in a minority cohort.

*Shylandra B. Sreenivasappa*

9D #1601-Influence of market access conditions on utilization of innovative drugs in Europe: The cases of trastuzumab and cetuximab.

*Jean-Louis Misset*

9E #1602-Molecular profiles of breast cancer in Ilorin, Nigeria.

*Kayode Adebamiji Adeniji, BSc, MBChB*

9F #1603-Colon cancer disparities: A SEER-based analysis of epidemiologic data on Asian and Pakistani immigrants in the United States.

*Rubayat Naila Rahman*

9G #1604-Analysis of the geographical distribution of cancer in Israel.

*Aviad Zick*

9H #1605-Mammography-detected breast cancer among 40-49-year-old patients at a community-based cancer center: 1990-2008.

*Judith April Malmgren*

10A #1606-Thymic malignancies (TM) in the United States: A population-based study of incidence and survival trends.

*Matthew A Gubens, MD, MS*

10B #1607-Comorbidities of the underserved and minority patient with cancer presenting to a public safety-net hospital: A deterrent for clinical trial participation?

*Steven N. Wolff*

10C #1608-Characteristics of adult osteosarcoma patients: Results from an ongoing postmarketing drug safety surveillance study.

*Kirk Midkiff, MPH*

**Session Title:** #205: Leukemia, Myelodysplasia, and Transplantation

**Session Type:** General Poster Session

**Date:** Saturday, June 5

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

11B #6534-Thymic renewal and antileukemic effect in adults after haploidentical transplantation and suicide gene therapy.

*Claudio Bordignon*

11F #6535-First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol.

*Damiano Rondelli*

11G #6536-EPOCH-FR: A novel salvage regimen for patients with lymphoid malignancies being considered for reduced-intensity allogeneic hematopoietic stem cell transplantation.

*Rachel B Salit*

11H #6537-A prospective feasibility study of clofarabine (CLO) cyto-reduction prior to allogeneic stem cell transplant (HCT) conditioning for refractory leukemia and MDS.

*Frederick Lundry Locke*

12A #6538-90y-ibrutinomab tiuxetan followed by reduced-intensity conditioning (RIC) and allogeneic stem-cell transplantation (SCT) in patients with high-risk relapsed, refractory, or transformed follicular lymphoma (FL).

*Karim Abou-Nassar*

12B #6539-Treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapsing after allogeneic hematopoietic cell transplantation (HCT).

*Alexandre Chiattonne*

12F #6540-Single-nucleotide polymorphism analysis of candidate genes in chronic GVHD.

*William B. Clark*

12G #6541-Pharmacokinetics and assessment of renal toxicity of a clofarabine (Clo), melphalan (Mel), and alemtuzumab (Alm) conditioning regimen.

*Koen van Besien, MD*

12H #6542-Is there a relationship between glucocorticoid (GC) dose and performance on functional outcome measures?

*Janet S. Scheetz*

13A #6543-Phase I dose-escalation trial of high-dose melphalan (M) with palifermin (P) for cytoprotection followed by autologous stem cell transplantation (ASCT) for myeloma (MM) patients with normal renal function (NRF).

*Muneer Hyder Abidi*

13B #6544-CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: Potential predictor of early engraftment.

*Kumar Prabhash*

13C #6545-Results of new cases of APL treatment by arsenic trioxide and long-term follow-up: Is it time for using arsenic trioxide in first-line treatment?

*Ardeshir Ghavamzadeh*

13D #6546-Use of deep whole transcriptome sequencing in Philadelphia-positive acute lymphoblastic leukemia (ALL) to identify novel mutated genes and aberrant gene expression and alternative splicing profiles associated with disease progression.

*Ilaria Iacobucci*

13E #6547-The relationship of cigarette smoking to invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients undergoing induction chemotherapy (IC).

*Mary George Mansour*

13F #6548-Dynamic of morphologic and molecular remission in patients (pts) with APL treated with frontline ATRA and arsenic trioxide (ATO).

*Mohamad Ayoubi*

13G #6549-Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies.

*Andrea Dean*

13H #6550-Correlation of *RASGRP1/APTX* ratio with clinical response and survival in AML patients treated with tipifarnib-bortezomib combination.

*Giovanni Martinelli*

14A #6551-Analysis of survival of older patients with frontline AML treated with clofarabine with or without low-dose cytarabine or intermediate-dose cytarabine: A matched cohort comparison.

*Stefan Faderl*

14B #6552-Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML).

*Gautam Borthakur*

14C #6553-Association of lymphocytosis following treatment with dasatinib with response and outcome.

*Charles Alan Schiffer*

14D #6554-Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients.

*Simona Soverini*

14E #6555-Decitabine therapy in patients with AML or MDS and chromosome 5, 7, or 8 abnormalities.

*Sanjay R. Mohan*

14F #6556-Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd.

*Timothy P. Hughes*

14G #6557-Long-term outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML.

*David Rizzieri*

14H #6558-A clinico-genomic model of performance status in acute myeloid leukemia.

*Arati Rao*

15A #6559-Obesity, a risk factor for acute myeloid leukemia? Roswell Park Cancer Institute weighs in on the obesity debate.

*Hun Ju Lee*

15B #6560-Patient and disease characteristics of women with acute myelogenous leukemia (AML) and a history of breast cancer (BC).

*Rana R Yehia*

15C #6561-Hypocellular acute myeloid leukemia: Better or worse prognosis.

*Aref Al-Kali*

15D #6562-The role of FLT3 in sole trisomy 8 acute myeloid leukemia.

*Anne Marie W. Block*

15E #6563-The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ALL.

*Sung-Nam Lim*

15F #6564-Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS).

*David A Macdonald*

15G #6565-Survival outcomes after initial infused therapy for elderly chronic lymphocytic leukemia (CLL) patients.

*Mark Danese*

15H #6566-Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

*Yiming Chen*

16A #6567-BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

*Dong-Wook Kim*

16B #6568-Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies.

*Jeffrey Howard Lipton*

16C #6569-Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.

*Giuseppe Saglio, MD*

16D #6570-Race and overall survival in acute myeloid leukemia.

*Jason M. Bierenbaum*

16E #6571-Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine.

*Amber Fullmer*

16F #6572-CPX-351 IN AML after failed induction with cytarabine and daunorubicin.

*Jeffrey E. Lancet, MD*

16G #6573-Incidence of unconventional infections (UC) in patients with acute myelogenous leukemia (AML) treated with clofarabine (CLO)-containing induction therapy.

*Randall W Knoebel, PharmD*

16H #6574-Activity of azacitidine in chronic myelomonocytic leukemia.

*Rubens Barros Costa*

17A #6575-BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.

*April H. Teitelbaum*

17B #6576-Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN- $\gamma$ ) treatment.

*Jack D. Burton*

17C #6577-Central nervous system disease and acute myeloid leukemia or chronic myeloid leukemia: Cytogenetic profile.

*Ferial Shihadeh*

17D #6578-A phase III randomized, double-blind, placebo controlled trial of North American (NA) ginseng (*Panax quinquefolium*) Extract (CVT-E002) in patients with chronic lymphocytic leukemia: Effect on respiratory infection and antibiotic use.

*Kevin P. High*

17E #6579-Epidemiology, risk factors, and outcomes of invasive fungal infection in adults with acute myelogenous leukemia undergoing intensive induction chemotherapy.

*Kit Lu*

17F #6580-Family history (FH) of women with breast cancer (BC) and acute myelogenous leukemia (AML).

*Kim A Reiss*

17G #6581-Serum interleukin-6, cardiovascular disease, and mortality in chronic lymphocytic leukemia.

*David E Dawe*

17H #6582-Treatment-related AML and AML evolving from MDS: Similar outcomes following treatment with amonafide plus cytarabine.

*Mikkael A. Sekeres*

18A #6583-Lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia: Report of an ongoing study.

*Danelle Frances James*

18B #6584-Four routinely recorded parameters define four distinct prognostic groups in AML.

*Juergen R Novotny*

18C #6585-United States (US) practices for chronic myelogenous leukemia (CML) management compared to other countries: A worldwide observational registry.

*Robert C. Hermann*

18D #6586-Effect of the presence of P-glycoprotein (MDR1) on the ability of AML patients to achieve complete remission: Results of a meta-analysis of the literature.

*Jean Pierre Marie*

18E #6587-Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older.

*Martha Lucia Arellano*

18F #6588-Early intensification of imatinib treatment based on precise definition of accelerated phase in patients with chronic myeloid leukemia: Population-based analysis.

*Kajetana Foryciarz*

18G #6589-High-dose of daunorubicin as induction treatment for adults with newly diagnosed Philadelphia-negative acute lymphoblastic leukemia.

*Sang Min Lee*

18H #6590-Prevalence of familial malignancy in a prospectively screened cohort of patients with leukemia.

*Aakanksha Prasad*

19A #6591-Detection of combinations of cytogenetic abnormalities in chronic lymphocytic leukemia (CLL) by fluorescent in situ hybridization (FISH) probes.

*Michael Thomas Schweizer*

19B #6592-Molecular characterization of normal karyotype acute myeloid leukemia in Korean patients.

*Yunsuk Choi*

19C #6593-Reactivation of latent viral hepatitis infection in patients of chronic myeloid leukemia treated with imatinib mesylate: Experience from a tertiary cancer center in India.

*Vikas Ostwal*

19D #6594-Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib.

*Nikhil Ghadyalpatil*

19E #6595-Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia patients: An Indian experience.

*Ritwik Pandey*

19F #6596-Meta-analysis of cord blood transplantations for indication of leukemia from private umbilical cord blood banks from 1993-2009.

*Nina Gottschalk*

19G #6597-Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs).

*Sameh Gaballa*

19H #6598-Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.

*Pierre Fenaux*

20A #6599-JAK2 V617F mutation positives in the general population.

*Stig E. Bojesen*

20B #6600-Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes (MDS).

*Edward Kim, MD, MBA*

20C #6601-Hematologic outcomes of MDS treatment with hypomethylating agents in community practice.

*Rodolfo Bordoni*

20D #6602-Increased of overall survival (OS) and malignancies (K) during tyrosine kinase inhibitors (TKI) in a real life cohort of patients (pts) with a chronic myeloid leukemia (CML).

*Marie-Pierre Gourin*

20E #6603-Eltrombopag effect on the engraftment efficiency of human hematopoietic stem cells in a NOD/SCID xenotransplant model.

*Yuhchyan Chen, MD, PhD*

20F #6604-Nonsteroidal anti-inflammatory drugs (NSAIDs) or EP4 receptor antagonism enhances hematopoietic stem and progenitor cell (HSPC) mobilization and facilitates faster hematopoietic recovery after myeloablation.

*Jonathan Hoggatt*

20G #6605-Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS).

*Naveen Pemmaraju*

20H #6606-Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes.

*Ghulam J. Mufti*

21A #6607-Phase II study of the histone deacetylase (HDAC) inhibitor belinostat for the treatment of myelodysplastic syndrome (MDS).

*Amanda F. Cashen*

21B #6608-Identification of genes with different methylation profiles between RAEB and RCMD in myelodysplastic syndrome.

*Suee Lee*

21C #6609-Effect of phosphoinositide-phospholipase c beta1 monoallelic deletion in low-risk MDS patients treated with darbepoetin.

*Pietro Spadaro*

21D #6610-In vitro activation of CMV-specific T-cell response using CyaA toxoids delivering peptide antigenic epitopes derived from pp65 protein.

*Jiri Jelinek*

21E #6611-Myelodysplastic syndrome (MDS) patients at a VA medical center: Comorbidity and survival.

*Katherine Kim*

21F #6612-A prospective multicenter observational study for decitabine treatment in &Kappa;orean patients with myelodysplastic syndrome.

*Je-Hwan Lee*

---

**Session Title:** #208: Lymphoma and Plasma Cell Disorders

**Session Type:** General Poster Session

**Date:** Saturday, June 5

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

22A #8047-Romidepsin activity in all three disease compartments (skin, blood, lymph nodes) in patients with cutaneous T-cell lymphoma (CTCL).

*Ellen Kim*

22B #8048-Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma.

*Barbara Pro*

22C #8049-Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell lymphoma: Results of the phase II RAIL trial-A prospective study of the Groupe d&rsquo;Etude des Lymphomes de l&rsquo;Adulte (GELA).

*Bertrand Joly*

22D #8050-Transcriptome adaptation caused by vorinostat/bexarotene combination therapy in advanced cutaneous T-cell lymphoma.

*Maria B. Karpova*

22E #8051-Prognosis and treatment of patients with peripheral T-cell lymphoma: The M. D. Anderson Cancer Center experience.

*Jenny Vu Pozadzides, MD*

22F #8052-Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma.

*Kein-Leong Yim*

22G #8053-Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous t-cell lymphoma (CTCL).

*David J. Straus, MD*

22H #8054-Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival.

*Andrei R. Shustov*

23A #8055-Duration of response in three phase III studies of denileukin diftitox in cutaneous T-cell lymphoma (CTCL).

*Madeleine Duvic*

23B #8056-T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant.

*Francesca Montanari*

23C #8057-ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A ten-year follow-up study.

*Nicolas Batty*

23D #8058-Does a negative post-therapy PET obviate the need for any further follow-up imaging in patients with nonbulky early-stage Hodgkin's lymphoma (HL)?

*Andrea Gallamini*

23E #8059-Clinically significant delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: A population-based study.

*David C. Hodgson*

23F #8060-Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT.

*Carmen Martinez*

23G #8061-Correlation of FDG-PET results after one cycle and after two cycles of chemotherapy in Hodgkin lymphoma.

*Martin Hutchings*

23H #8062-Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series.

*Nancy Bartlett, MD*

24A #8063-Body mass index (BMI) and obesity as a predictor of clinical outcome in patients with Hodgkin's lymphoma treated with AVBD.

*Ritesh Patil*

24B #8064-Results of the SMARTE-r-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).

*Michael Pfreundschuh*

24C #8065-Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL).

*Kerri A Pierz*

24D #8066-Phase II study of short course CHOP-rituximab followed by 90-y ibritumomab tiuxetan as first-line treatment for follicular lymphoma: Extended follow-up and predictors of relapse.

*Dhaval R. Mehta, MD*

24E #8067-Frontline therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) lead to superior outcome in mantle cell lymphoma (MCL).

*Tatyana Feldman*

24F #8068-CD137 stimulation of natural killer cells to enhance the antilymphoma activity of rituximab.

*Holbrook Edwin Kohrt*

24G #8069-Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

*Corinne Haioun*

24H #8070-Correlation of the intra-tumor phospholipid-related signatures determined noninvasively by phosphorus and hydrogen MR spectroscopy: An approach to increase the sensitivity and applicability of the technique to predict therapeutic outcome in non-Hodgkin's lymphoma.

*Fernando Arias-Mendoza*

25A #8071-Duration of remission using I-131 tositumomab in patients with B-cell lymphoma relapsing after autologous stem cell transplant.

*David Douglas Shepard*

25B #8072-Diffuse large b-cell lymphoma (DLBCL) with bone marrow (BM) involvement. clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at m. d. anderson cancer center.

*Guilherme F Perini*

25F #8073-Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma (FL) treated with radiotherapy.

*Puneet Bains*

25G #8074-Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factors in 40 consecutive Asian patients.

*Wai Meng David Tai*

25H #8075-Immunochemotherapy with rituximab in combination with fludarabine and epirubicin as first-line treatment in patients with chronic lymphocytic leukemia.

*Kai Uwe Chow*

26A #8076-CpG oligodeoxynucleotides directly suppress the growth of aggressive human B-cell lymphomas.

*Reiko E Yamada*

26B #8077-Clinical characteristics of non-Hodgkin's lymphoma (NHL) in Vietnam era (V) and non-Vietnam era veterans (Non V).

*Shanthi Srinivas*

26F #8078-Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL).

*George Edward Manoukian, MD*

26G #8079-Comparison of contrast-enhanced CT, PET/CT, PET, and low-dose non-contrast enhanced CT imaging of diffuse large B-cell (DLBCL), follicular (FL), small lymphocytic/CLL (CLL/SLL), and marginal zone lymphomas (MZL).

*Elise A Chong*

26H #8080-Association of serum B7-H1 level and lymphopenia in diffuse large B-cell non-Hodgkin lymphoma.

*Ryan A. Wilcox*

27A #8081-High-dose sequential chemotherapy and rituximab (R-HDS) supported by autologous stem cell transplantation (ASCT) in patients (pts) with systemic B-cell lymphoma with CNS involvement (SCNSL) at diagnosis or relapse: Interim analysis of feasibility and activity of a phase II trial.

*Andrea Assanelli*

27B #8082-Quality of life in 269 poor risk diffuse large B-cell lymphoma patients treated with rituximab versus observation after front-line auto transplantation: The GELA LNH98-3 randomized trial.

*Nicolas Mounier*

27C #8083-Clinicopathological differences between EBV-positive and EBV-negative diffuse large B-cell lymphoma.

*Brady Ernesto Beltran*

27D #8084-Maintenance rituximab versus observation after R-CHOP or R-EPOCH in patients with untreated poor-prognosis diffuse large B-cell lymphoma and grade III follicular lymphoma.

*Ya jun Li*

27E #8085-Changes in regulatory T-cells in responding and non-responding patients with indolent B-cell or mantle cell lymphomas during treatment with lenalidomide, dexamethasone and rituximab.

*Nicole Aquí*

27F #8086-Phase II study of MGCD0103 in patients with relapsed follicular lymphoma (FL): Study reinitiation and update of clinical efficacy and safety.

*Robert E. Martell*

27G #8087-Effect of YM155, a potent survivin suppressant, on the antitumor effect of rituximab in diffuse large B-cell lymphoma (DLBCL) xenograft models: FLT-/FDG-PET imaging studies.

*Keisuke Mitsuoka, PhD*

27H #8088-Hypogammaglobulinemia in pts receiving rituximab immunotherapy and the impact of rituximab maintenance.

*Carla Casulo, MD*

28A #8089-Clinical relevance of a positive result in cerebrospinal fluid (CSF) by flow cytometry (FCM) in patients with diffuse large B-cell lymphoma (DLBCL).

*Rute Alvarez*

28B #8090-Correlation of tumoricidal activity of lenalidomide against hematologic tumor cells with cyclin D1/D2 expression and effect on tumor-suppressor gene upregulation.

*Ling-Hua Zhang*

28C #8091-Participation of elderly patients with lymphoma and myeloma in clinical trials of novel agents.

*Jia Ruan*

28D #8092-The association between the mantle cell lymphoma international prognostic index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate-AraC (R-MTX-AraC).

*Anthony R. Mato*

28E #8093-Effect of inactivation of argininosuccinate synthetase on sensitivity of lymphomas to caspase-dependent apoptosis following treatment with arginine deiminase.

*Peter Wojciech Szlosarek*

28F #8094-Efficacy of combination of rituximab (R), obatoclox (O) and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL).

*Wasif Riaz*

28G #8095-Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.

*Matthew John Barth, MD*

28H #8096-Rituximab-related (R-R) reactivation of hepatitis B virus (HBV) in lymphoma: Analysis of FDA safety reports and a systematic literature review with meta-analysis.

*Andrew M. Evens*

29A #8097-Late phase II study of amrubicin in previously untreated patients with non-Hodgkin's lymphoma (NHL).

*Junji Suzumiya*

29B #8098-Effect of a rituximab-based regimen on the incidence of CNS relapse in patients with diffuse large B-cell lymphoma.

*Mervat Mahrous*

29C #8099-Cladribine plus rituximab for the initial treatment of mantle cell lymphoma.

*Talia Pindyck*

30A #8100-Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL).

*Christopher Flowers*

30B #8101-Prognostic value of the absolute lymphocyte count reduction in patients with diffuse large B-cell lymphoma treated with R-CHOP.

*Shinae Kim*

30C #8102-18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus FLIPI as a predictor of therapy response in follicular lymphoma (FL) patients.

*Dominick Michael Lamonica*

31A #8103-Maximum standardized uptake (SUVmax) on initial 18 FDG-PET/CT as prognostic value in patients with diffuse large B-cell lymphoma.

*BoRan Kwon*

31B #8104-Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).

*David Belada*

31C #8105-Radioimmunotherapy for consolidation and relapse therapy for aggressive B-cell non-Hodgkin lymphoma: Retrospective analysis of the International RIT-Network.

*Karin Hohloch*

32A #8106-A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis.

*Vicki A. Morrison, MD*

32B #8107-Maintenance rituximab is associated with improved clinical outcome in rituximab-naïve patients with Waldenstrom's macroglobulinemia (WM) who respond to a rituximab-containing regimen.

*Leukothea I Ioakimidis*

32C #8108-Association of CR/VGPR with progression-free survival in rituximab-naïve WM patients undergoing rituximab-based therapy, as predicted by polymorphisms in FcγRIIIA-158.

*Zachary R Hunter*

33A #8109-Long-term follow-up of patients with lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia) who were treated with alemtuzumab.

*Jacob D Soumerai*

33B #8110-Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenstrom's macroglobulinemia, and effect on miRNA expression.

*Douglas W McMillin*

33C #8111-Association of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, with MGUS and multiple myeloma in different ethnic groups.

*Sandra Grass*

34A #8112-Activity of the CD20-directed monoclonal antibody GA101 relative to rituximab in Waldenstrom's macroglobulinemia (WM), and applicability to patients expressing FcγRIIIA-158 F/F.

*Guang Yang*

34B #8113-Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma.

*Herve Avet-Loiseau*

34C #8114-Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM).

*Steven P. Treon*

35A #8115-Racial disparities in incidence and survival among 37,977 blacks and whites with multiple myeloma.

*Adam J Waxman*

35B #8116-Primary plasma cell leukemia (PCL): Clinical and laboratory presentation and clinical outcome with total therapy (TT) protocols.

*Bijay P. Nair*

35C #8117-Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications.

*Christoph Johann Heuck*

35D #8118-BIK (Bcl2-Interacting Killer) CpG methylation status as a potential predictive biomarker of relapsed/refractory multiple myeloma disease.

*Eleftheria Hatzimichael*

35E #8119-Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM).

*John Crowley*

35F #8120-Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression profiling (GEP) signatures.

*Antje Hoering*

35G #8121-Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).

*Frits Van Rhee*

35H #8122-Gene expression profiling (GEP) in multiple myeloma (MM): Distinguishing relapses with high-risk transformation from those with sustained low risk.

*Jeffrey Sawyer*

36A #8123-Metaphase cytogenetic abnormalities (M-CA) in multiple myeloma (MM): Examining number of m-CA for survival in total therapy protocols (TT1, TT2, TT3).

*Jeff Haessler*

36B #8124-Expression of erythropoietin receptors by plasma cells from patients with multiple myeloma: Potential relevance to pharmacological use of erythropoietin.

*Pamela S Becker*

36C #8125-Treatment patterns and outcome among patients with multiple myeloma relapsing and or refractory to bortezomib and immunomodulatory drugs: A multicenter International Myeloma Working Group study.

*Shaji K Kumar, MD*

36D #8126-Gene expression profiling (GEP) analysis of CD138-purified plasma cells (PC) obtained from MRI-defined focal lesions (FL) under CT guidance: Applying the 70 gene risk model and comparison with data generated on random samples (RS) from multiple myeloma (MM) treated with total therapy 2, 3, 4 and 5 (TT2, TT3, TT4 and TT5).

*Ya-wei Qiang*

36E #8127-Retrospective analysis of multiple myeloma survival outcomes in veterans: Focus on racial differences, age, and novel therapies.

*Daniel I Da Graca*

36F #8128-Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.

*Ashraf Z. Badros*

36G #8129-Bortezomib and high-dose melphalan as conditioning regimen before transplantation for de novo multiple myeloma patients: Updated data of the IFM phase II study.

*Murielle Roussel*

36H #8130-MP versus MPT for previously untreated elderly patients with multiple myeloma: A meta-analysis of 1,682 individual patient data from six randomized clinical trials.

*Anders Waage*

37A #8131-A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM).

*Meaghan L Khan*

37B #8132-Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM).

*Jatin J. Shah*

37C #8133^ -Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).

*Sundar Jagannath*

37D #8134-A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).

*James R. Berenson, MD*

37E #8135-Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI).

*Jeffrey Lee Wolf*

37F #8136-The Arkansas experience with autotransplantation (AT) for older patients (OP, age >65) with multiple myeloma (MM).

*Elias J. Anaissie*

37G #8137-Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study.

*Andreas Guenther*

37H #8138-Predicting 10+ year survivors in total therapy 1 (TT1) for multiple myeloma (MM).

*Sarah Waheed*

38A #8139-A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma.

*Don M. Benson*

38B #8140-Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.

*Noopur S. Raje, MD*

38C #8141-Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor.

*Saad Usmani*

38D #8142-Is low-dose cyclophosphamide (Cy) plus G-CSF (G) mobilization as effective as plerixafor plus G in multiple myeloma (MM) patients (pts) who are candidates for tandem autologous transplants (autoT)?

*Chatchada Karanes, MD*

38E #8143-A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients.

*Andrew Spencer*

38F #8144-An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission.

*Tomer Martin Mark*

38G #8145-Single/tandem autologous hematopoietic progenitor cell transplantation in high-risk de novo multiple myeloma patients: A retrospective analysis.

*Massimo Vincenzo Martino*

38H #8146-Does the magnitude of response to initial induction therapy impact plans for immediate autologous stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)?

*Joanne Willey*

39A #8147-Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies.

*Peter Lee*

39B #8148-Use of combined FDG-PET and laboratory data for predicting relapse in multiple myeloma.

*Brian M Elliott*

39F #8149-Stromal elements and engraftment (ENG) in autologous hematopoietic progenitor cell transplant (autoHCT) for myeloma.

*Muthu Veeraputhiran*

39G #8150-Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging.

*Karim Belhadj*

39H #8151-Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (The BoMeR trial): Impact on response and time to progression.

*Simon James Harrison*

**Session Title:** #213: Tumor Biology

**Session Type:** General Poster Session

**Date:** Saturday, June 5

**Location:** S Hall A2

**Time:** 8:00 AM - 12:00 PM

40A #10538-EGFR mutations in men and cigarette smokers with lung adenocarcinoma.

*Maria Catherine Pietanza*

40B #10539-Molecular types and prognostic markers uPA/PAI-1 for 2,497 early breast cancer patients in the multicenter, randomized NNBC 3-Europe trial.

*Eva Johanna Kantelhardt*

40F #10540-Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: A prospective, phase II trial.

*John D. Hainsworth*

40G #10541-Effect of IKK&epsilon; knock-down on prostate cancer xenograft growth.

*Benjamin Péant, PhD*

40H #10542-Immunohistochemistry detection of epidermal growth factor receptor (EGFR) exons 19 and 21 mutations in non-small cell lung cancer (NSCLC) using novel mutation specific antibodies.

*Yasufumi Kato, MD, PhD*

41A #10543-Analysis of the methylation profile of 49 cancer-related regions in human breast cancer.

*Diego Matias Marzese*

41B #10544-Prospective multicentric trial evaluating prognostic and predictive value of circulating tumor cells in first-line chemotherapy metastatic breast patients.

*Jean-Yves Pierga*

41C #10545-Effect of kinesins on taxane resistance.

*Robert Wesolowski*

41D #10546-Impact of high-risk classification by FISH on overall survival in myeloma: An Eastern Cooperative Oncology Group (ECOG) study E4A03.

*Susanna J. Jacobus*

41E #10547-Early operable primary breast cancer in elderly ( $\geq$  70 years) women: Are they biologically different from their younger counterparts?

*Kwok-Leung Cheung*

41F #10548-Can cetuximab specific IgE antibodies predict cetuximab-induced anaphylaxis?

*Benoît Dupont*

41G #10549-Determining true HER2 status in breast cancers with polysomy using alternative chromosome 17 reference genes: Implications for trastuzumab therapy.

*Allen M. Gown, MD*

41H #10550-Identification of DNA methylation changes in esophageal cancer before/after chemoradiation therapy using a MCA-microarray and bisulfate pyrosequencing.

*Takashi Tsuda*

42A #10551-Prediction of response to neoadjuvant therapy in breast cancer using plasma and tumor proteomic analyses.

*Christophe Desauw*

42B #10552-Value of quantitative DNA fingerprinting in classification of second breast tumors and association with outcome.

*Benjamin L Schlechter*

42C #10553-CpG-b oligodeoxynucleotides potently activate human NK cells and sensitize chronic lymphocytic leukemia cells to NK cell-mediated killing.

*Veronika Bachanova*

42D #10554-Use of a combination of 5-fluorouracil pathway genes to predict treatment outcome of S-1 monotherapy in advanced gastric cancer.

*Gun Min Kim*

42E #10555-Use of CD8 and Foxp3 immune infiltrates after neoadjuvant chemotherapy to predict survival in HER2-overexpressing breast cancer patients.

*François Ghiringhelli*

42F #10556-Efficient detection of *EGFR* alterations in lung adenocarcinomas.

*Marc G Denis*

42G #10557-Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood as a predictor of response to gefitinib.

*Jingxun Wu*

42H #10558-Biomarkers of early operable primary breast cancer in elderly (>= 70 years) women (EPC) and their correlation with breast cancer-specific survival (BCSS).

*Binafsha Manzoor Syed, MBBS*

43A #10559-Clinical significance of 18F-alpha-methyl tyrosine PET as a potential surrogate marker of LAT1 expression for predicting prognosis of non-small cell lung cancer.

*Noboru Oriuchi*

43B #10560-Correlation of expression of circadian genes with liver metastasis and outcomes in colorectal cancer.

*Takashi Oshima, MD, PhD*

43C #10561-Epigenetic silencing of Dab-2 in head and neck cancer.

*Cristiana Lo Nigro, Ph.D., D.Sc.*

43D #10562-The single-nucleotide polymorphism A>G rs397768 in APC gene as a new biomarker of response to chemotherapy in advanced colorectal cancer.

*José Carlos Villa Guzman*

43E #10563-Biomarkers of treatment benefit in a randomized phase II study of bevacizumab in combination with carboplatin and paclitaxel in metastatic melanoma patients (BEAM).

*Priti Hegde*

43F #10564-Use of peripheral blood mRNA signatures to distinguish colorectal cancer patients from colonoscopy-negative patients.

*Ye Xu*

43H #10566-Application of kinase activity profiles to predict response to erlotinib in a neoadjuvant setting in early stage non-small cell lung cancer (NSCLC).

*Riet Hilhorst*

44A #10567-Prognostic value of serum protein biomarkers in patients with epithelial ovarian cancer.

*Meiyao Wang*

44B #10568-Relationship of expression level of CD133 with tumor angiogenesis and prognosis of hepatocellular carcinoma after liver transplantation.

*Yang Xu*

44C #10569-Lung cancer autoantibody signature as indicator of early disease.

*Tetyana V. Pedchenko*

44D #10570-Evaluation of the prognostic value of UBE2C mRNA levels in early breast cancer.

*Diamando Psyrrri*

44E #10571-Use of T-cell proliferation to predict survival and recurrence in patients with resected colorectal liver metastases.

*Ajay V Maker*

44F #10572-Biomarker profiles and changes from baseline in trastuzumab (T) refractory HER2-positive inflammatory breast cancer (IBC) that predict decreases in tumor burden from lapatinib (L) monotherapy.

*Stephen R. D. Johnston*

44G #10573-Markers of anaerobic glycolysis as predictive factor in neoadjuvant chemoradiotherapy of rectal cancer.

*Der Sheng Sun*

44H #10574-SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and *nab*-paclitaxel (*nab*-P) in locally advanced breast cancer (LABC).

*Denise Aysel Yardley*

45A #10575-Gene expression differences in current versus former smokers lung squamous preneoplasia.

*Celine Joselyne Monique Mascaux*

45B #10576-Molecular profiling of pulmonary pleomorphic carcinoma: Implications for targeted treatment of a rare lung malignancy.

*Youngwook Kim*

45C #10577-Role of the type III TGF- $\beta$  receptor in mediating immunosuppression during breast cancer progression.

*Brent Allen Hanks*

45D #10578-Use of circulating and tumor-infiltrating myelomonocytic cells to predict survival in human malignant pleural mesothelioma (MPM).

*Bryan Burt*

45E #10579-Impact of a gene expression-based tissue of origin test on diagnosis and recommendations for first-line chemotherapy.

*Marianne Laouri*

45F #10580-Circulating exosomes may provide a more sensitive platform to monitor disease progression compared to circulating tumor cells.

*Traci L Pawlowski, PhD*

45G #10581-Use of peripheral blood mRNA signature to distinguish patients with breast cancer from benign breast disease and nonconclusive mammography.

*BenLong Yang*

45H #10582-Predictive value of the Theros Breast Cancer Index (TBCI) for distant recurrence and overall survival (OS) in comparison to Adjuvant! Online and clinicopathologic characteristics in women with lymph node (LN)-negative, ER-positive breast cancer (BCa).

*Rachel Catherine Jankowitz*

46A #10583-MST1R, a receptor tyrosine kinase expressed in malignant pleural mesothelioma.

*David Easty*

46B #10584-Protein expression (PE) and increased IGF1R gene copy number (GCN) in small cell lung cancer (SCLC).

*Andrzej Badzio*

46C #10585-Evaluation of macrophage inflammatory protein-3 alpha (MIP-3a) as a serum marker for prognosis of colorectal cancer.

*Takashi Iwata*

46D #10586-Feasibility of a prospective host cell reactivation assay (HCRA) in non-small cell lung cancer (NSCLC) patients.

*Pedro Mendez*

46E #10587-D-dimer levels and prediction of overall survival in cancer patients.

*Cihan Ay, MD*

46F #10588-The prognostic relevance of CXC-chemokines in stage II and III colorectal cancer (CRC) tissue and inflammatory infiltrate.

*Olabode Oladipo*

46G #10589-Relations of circadian clocks genes with endocrine, proliferation, differentiation, and P53 mutation status in human locally invasive primary breast cancer.

*Ida Iurisci*

46H #10590-Race and the influence of p53 as a marker of prognosis in women of lower SES with breast cancer.

*Keith A. Dookeran, MD, MBA*

47A #10591-Primary resistances to EGFR inhibitors (EGFRi) in HPV-positive and -negative oropharyngeal squamous cell carcinoma (OSCC).

*Federica Perrone*

47B #10592-Implication of the alternative NF-kappa B pathway in prostate cancer progression.

*Ingrid Labouba*

47C #10593-Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB).

*Emily Gustava Lipsitz*

47D #10594-Use of protein pathway activation mapping of NSCLC to identify distinct molecular subtypes and a prognostic signature for aggressive node-negative tumors.

*Angela Zupa*

47E #10595-Nuclear expression of aryl hydrocarbon receptor and prognosis for non-small lung cancer.

*Han Chang, MD, PhD*

47F #10596-Preclinical in vivo evaluation of a novel treatment strategy combining a Wee1 inhibitor with radiotherapy.

*Kathy Mason*

47G #10597-Antagonists of growth hormone-releasing hormone potentiate radiation response in prostate cancer.

*May Abdel-Wahab, MD, PhD*

47H #10598-Clinico-pathologic features of lung cancer with EML4-ALK translocation.

*Tetsuya Mitsudomi*

48A #10599-Evaluation of ADAM28 as a serological and histochemical marker for non-small cell lung cancers.

*Hiroaki Kuroda*

48B #10600-Effect of plasma SPARC on outcome in cancer models.

*Neil Desai*

48C #10601-Evaluation of the hedgehog pathway as a therapeutic target for preventing the progress to invasive-stage from noninvasive-stage breast cancer.

*Masae Sozaki, MD*

48D #10602-Effect of zoledronic acid acts on the interaction between mesenchymal stem cells and breast cancer cells within the bone microenvironment.

*Nicola Normanno*

48E #10603-Clinical relevance of the detection of tumor cells in the bone marrow of patients before lung cancer surgery.

*Rie Nakahara*

48F #10604-Molecular markers for epithelial-mesenchymal transition (EMT) and tumor aggressiveness in breast carcinoma.

*Seema Sethi*

48G #10605-Risk partitioning model shows need to address time dependence of breast cancer recurrence.

*Laura Esserman*

48H #10606-Role and prognostic value of placenta growth factor (PlGF) in colorectal carcinomas.

*Moo Jun Baek*

49A #10607-Evaluation of gene expression signatures induced by stromal factors as a predictor of survival in breast cancer.

*Inke Luehr*

49B #10608-BRCA1 expression evaluated by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in operable breast cancer.

*Piotr Potemski*

49C #10609-Gene set comparison analyses of gene expression signatures for the acquired chemotherapy resistance.

*Hark K. Kim*

49D #10610-Activation of the PI3K pathway and prognostic information in epithelial ovarian cancer.

*Despina Debbie Handolias*

49E #10611-Inhibitor of differentiation-1 (Id1): A novel prognostic and predictive factor in lung adenocarcinoma (AC).

*Ignacio Gil-Bazo*

49F #10612-Comparison of folate derivate levels in mucosa and tumor tissue in the course of antifolate treatment with pemetrexed.

*Bengt Gustavsson*

49G #10613-Involvement of angiogenesis genes in pathologic response of advanced ovarian carcinoma.

*Marta Mendiola*

49H #10614-Tumor characteristics and patient outcomes in ductal compared with lobular carcinoma.

*Samah Nour*

50A #10615-Substratification of 70-gene high-risk breast cancers with a validated 80-gene molecular subtyping profile.

*Femke de Snoo*

50B #10616-Prognostic significance of immunoglobulin kappa C in node-negative breast cancer is both conserved across and independent from molecular subtypes.

*Marcus Schmidt*

50C #10617-C-src: A potential target for the treatment of triple-negative breast cancer.

*Siun Walsh*

50D #10618-Cancers involving the lung mediate human marrow cell phenotype change.

*Peter J. Quesenberry*

50E #10619-Metabotropic glutamate receptor-1: A new molecular target for the therapy of triple-negative breast cancer.

*David H. Gorski*

50F #10620-Use of protein pathway mapping of brain metastasis from breast and lung cancer patients to identify new therapeutic targets: A seed/soil study.

*Giuseppina Improta*

50G #10621-Triple negative breast cancers: Biomarkers and outcomes.

*Luca Malorni*

50H #10622-Effect of matrix metalloproteinase-2 on the ability of human dendritic cells to prime inflammatory TH2 cells via an IL-12 and OX40L dependent pathway.

*Emmanuelle Godefroy*

51A #10623-Plasma levels of VEGF-A and VEGFR-2 in advanced NSCLC.

*Elena Sanmartin*

51B #10624-Use of quantum dots-based immunofluorescence nanotechnology for quantitative HER2 and ER detection in breast cancer tissue array to identify correlations in HER2-overexpressed and ER-positive breast cancer.

*Chuang Chen*

51D #10626-Toll-like receptor (TLR) 7 and TLR8 expression in CD133+ cells in colorectal cancer and role for inflammation-induced TLRs in tumorigenesis and tumor progression.

*Martin Gasser*

51E #10627-Detection of aberrant *SHP-1* promoter methylation, an implication in advanced non-small cell lung cancer.

*Chanida Vinayanuwattikun*

51F #10628-Neuropilin-2 and epithelial to mesenchymal transition in colorectal cancer cells.

*Camille Grandclement*

51G #10629-EMMPRIN up-regulates VEGFR-2 through HIF-2alpha mediated mechanism: Consequences on angiogenesis and tumor progression.

*Faten Bougatef*

51H #10630-Evaluation of the combined expression of chemokine SDF-1 $\alpha$ ; and its receptor CXCR4 as a marker for prognosis in gastric cancer.

*Hyo Jin Lee*

52A #10631-Evaluation of CYP24A1 mRNA expression as a prognostic marker and predictor of calcitriol activity in lung adenocarcinoma.

*Nithya Ramnath, MD*

52B #10632-Integrated genomics-based discovery of new oncoproteins as a biomarker and a molecular target for lung cancer.

*Yataro Daigo*

52C #10633-Interim analysis of CALGB 150607: A pilot project to study the expression of MET and P53 in resected lung adenocarcinoma specimens.

*April K. Salama, MD*

52D #10634-DNA repair biomarker alterations in breast cancer relevant to adjuvant chemotherapy treatment decisions.

*Kam M Sprott*

52E #10635-MicroRNAs as a potential prognostic factor in gastric cancer.

*Ofer Purim*

52F #10636-Use of immunohistochemical profiling of node-negative breast carcinomas for prediction of metastatic risk.

*Colette Charpin*

52G #10637-Direct visualization of circulating sarcoma cells by whole-blood fluorescence in situ hybridization.

*Alexei Morozov*

52H #10638-Circulating tumor cells: Multimarker gene profile for tailoring chemotherapeutical response in adeno carcinomas.

*Nikos Fersis*

53A #10639-MMP-7 serum levels as predictor or prognostic of cetuximab benefit in the treatment of advanced colorectal cancer: Results from a HCB-05 prospective trial.

*Gemma Carrera*

53B #10640-HIF-1 $\alpha$ ; and EGFR as prognostic factors for therapy response and 1-year locoregional recurrence not for distant metastasis and 2-year OS in unresectable stage IIIA NSCLC treated with combined chemoradiotherapy.

*Yanqin Yang*

53F #10641-Correlations of mRNA expression levels of genes in the targeted pathways and Kras mutation status in patients with colorectal cancer.

*Dongyun Yang*

53G #10642-Prediction of survival in early stage non-small cell lung cancer based on kinase activity profiles.

*Rob Ruijtenbeek*

53H #10643-Analysis of the prognostic role of regulatory T-lymphocyte-associated marker expression in resectable NSCLC.

*Marta Usó*

54A #10644-Role of antiapoptotic STAT3 and BCL-2 signaling in promoting lung tumor cells to survive against combined MET-/EGFR-targeted inhibitors.

*Patrick C. Ma, MD, MSc*

54B #10645-Pregnancy-associated breast cancer: Characterization and potential chemoprevention with anti-inflammatory treatment.

*Virginia F. Borges*

54F #10646-Correlation of PITX2 gene expression and invasive potential of breast cancer cells.

*Rebecca Aft, MD, PhD, FACS*

54G #10647-Correlation of the Oncotype DX recurrence score with a composite index comprised of ER, PR, HER2, and breast tumor grade.

*Joseph Geradts*

---

**Session Title:** #216: Genetic and Molecular Predictors in Genitourinary Malignancies

**Session Type:** Clinical Science Symposium

**Date:** Saturday, June 5

**Location:** E Hall D2

**Time:** 8:00 AM - 9:30 AM

- Genetic and Molecular Predictors in Genitourinary Malignancies

*Adam Stuart Kibel, MD*

- Genetic and Molecular Predictors in Genitourinary Malignancies  
*Andrew J. Armstrong, MD, ScM*
  - #4500-Predicting prostate-cancer-specific death: Is it in the cancer?  
*Gustavo E Ayala*
  - #4501-Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC).  
*Brian I. Rini*
  - #4502-Evaluation of the genetic component of early-onset prostate cancer.  
*Kathleen A. Cooney*
  - #4503-Susceptibility loci associated with prostate cancer progression and mortality.  
*David James Gallagher*
  - Discussion: Emerging evidence for a genetic risk of prostate cancer  
*Elaine Ostrander, PhD*
- 

**Session Title:** #222: Molecularly Targeted Trials in Lung Cancer

**Session Type:** Clinical Science Symposium

**Date:** Saturday, June 5

**Location:** E Hall D1

**Time:** 8:00 AM - 9:30 AM

- Molecularly Targeted Trials in Lung Cancer  
*Heather A. Wakelee, MD*
- Molecularly Targeted Trials in Lung Cancer  
*Marvaretta Miesha Stevenson, MD*
- #7500-Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).  
*Jacek Jassem*
- Discussion: IGF1R: Where do we go from here?  
*D. Ross Camidge, MD, PhD*
- #LBA7501-A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.  
*Joachim Von Pawel*

- Discussion: Where does this TRAIL lead us?

*Bruce E. Johnson, MD*

- #LBA7502-Results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

*Joan H. Schiller*

- Discussion: Combinations of targeted agents

*Ravi Salgia, MD, PhD*

---

**Session Title:** #322: Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications (Limited Seating Available)

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** S106a

**Time:** 8:00 AM - 11:00 AM

- Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications (Limited Seating Available)

*Hyman Bernard Muss, MD*

- Designing Clinical Trials for Older Patients: Laboratory Science and Practical Applications (Limited Seating Available)

*Kathryn A. Bylow, MD*

- Comparative Effectiveness

*Arash Naeim, MD*

- Defining Frailty

*Arti Hurria, MD*

- Biomarkers

*Norman E. Sharpless, MD*

- Decision Making

*William Dale, MD, PhD*

**Session Title:** #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

*Daniel D. Von Hoff, MD*

**Session Title:** #118: Germ Cell Tumors in Children, Adolescents, and Young Adults

**Session Type:** Meet the Professor Session

**Date:** Saturday, June 5

**Location:** E451b

**Time:** 9:45 AM - 11:00 AM

- Germ Cell Tumors in Children, Adolescents, and Young Adults

*A. Lindsay Frazier, MD*

**Session Title:** #136: Ocular Melanoma

**Session Type:** Clinical Problems in Oncology Session

**Date:** Saturday, June 5

**Location:** E451a

**Time:** 9:45 AM - 11:00 AM

- Background and treatment of primary ocular melanoma

*J. William Harbour, MD*

- Regional therapy for ocular melanoma

*James F. Pingpank, MD, FACS*

- Systemic therapy for metastatic ocular melanoma

*Takami Sato, MD, PhD*

**Session Title:** #239: Breast Cancer - Metastatic

**Session Type:** Poster Discussion Session

- Breast Cancer - Metastatic

*Anne F. Schott, MD*

- Breast Cancer - Metastatic

*Hope S. Rugo, MD*

1 #1012-A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).

*Kathy Miller, MD*

2 #1013- Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.

*Florence Dalenc*

3 #1014-Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2-overexpressing breast cancer.

*Phuong Khanh H. Morrow*

4 #1015-Correlation of cyclin D1, A870G, polymorphism and clinical outcome in patients with HER2-positive, metastatic breast cancer treated with lapatinib plus capecitabine.

*Melissa Janae Labonte*

5 #1016-Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.

*Patricia LoRusso, DO*

- Discussion

*David A. Cameron, MD*

7 #1018-Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.

*Rebecca Alexandra Dent*

8 #1019-A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.

*Steven J. Isakoff*

9 #1020-Activity of taxane chemotherapy for metastatic breast cancer (MBC) in BRCA1 and BRCA2 mutation carriers compared to sporadic BC patients.

*Caroline Seynaeve*

10 #1021-Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC).

*Adam Brufsky*

- Discussion

*Lisa A. Carey, MD*

11 #1022-A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study.

*Elke Jaeger*

12 #1023-Impact of first-line chemotherapy duration in metastatic breast cancer: A systematic review.

*Alessandra Gennari*

13 #1024-Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial.

*Alison Stopeck*

14 #1025-Effects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: Results from a randomized phase III trial.

*Lesley Fallowfield*

15 #1026-Ibandronate in the treatment of patients (pts) with breast cancer (BC) with metastatic bone disease (MBD): Final results of a large-scale noninterventional study (NIS).

*Ingo J. Diel*

- Discussion

*Catherine H. Van Poznak, MD*

16 #1027-The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases.

*Carey K. Anders*

17 #1028-A graded prognostic assessment (GPA) for women with breast cancer and brain metastases.

*Paul W. Sperduto*

18 #1029-Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.

*Anna Niwinska, MD, PhD*

19 #1030-Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in patients (pts) with metastatic breast cancer (MBC) treated with trastuzumab-containing therapy.

*Renata Duchnowska*

- Discussion

*Nancy U. Lin, MD*

20 #1031-Male breast cancer in veteran population: Retrospective analysis of VACCR database.

*Shanmuga Subbiah, MD, MBBS*

---

**Session Title:** #241: Central Nervous System Tumors

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S100b

**Time:** 12:00 PM - 1:00 PM

- Central Nervous System Tumors

*David Peereboom, MD*

- Central Nervous System Tumors

*Deric M. Park, MD*

1 #2009-ANG1005: Results of a phase I study in patients with recurrent malignant glioma.

*Jan Drappatz*

2 #2010-Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study.

*Karen Fink*

3 #2011-Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM).

*David Schiff, MD*

4 #2012-Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma.

*Jaishri O'Neill Blakeley*

- Discussion

*John L. Villano, MD, PhD*

5 #2013-Isotrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: A NABTT CNS consortium study.

*Stuart Grossman, MD*

6 #2014-Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).

*Rose Lai*

7 #2015-The efficacy of interferon- $\beta$  and temozolomide combination therapy for newly diagnosed primary glioblastoma: Multicenter study.

*Kazuya Motomura*

8 #2016-Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: Results from NCCTG N027D.

*Jann Nagina Sarkaria*

9 #2017-Testosterone levels in men undergoing treatment for malignant gliomas.

*Matthias Holdhoff*

- Discussion

*Martin Kelly Nicholas, MD, PhD*

10 #2018-NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

*Evanthia Galanis, MD*

11 #2019-Heterogeneity of response to bevacizumab in multifocal and multicentric glioblastomas.

*Shirley S. Ong*

12 #2020-Change in pattern of relapse in newly diagnosed high-grade glioma following bevacizumab therapy.

*Michael L. Gruber*

13 #2021-Radiographic patterns of relapse in glioblastoma.

*Marc C. Chamberlain, MD*

14 #2022-Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenic drugs?

*Enrico Franceschi, MD*

15 #2023-Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM).

*James J. Vredenburgh*

16 #2024-Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab.

*Jing Wu*

17 #2025-Deletion of NFKBIA in malignant gliomas.

*Markus Bredel*

18 #2026-Use of perfusion MR imaging for differentiation between tumor progression and pseudo-progression in recurrent glioblastoma multiforme.

*Christel Heidemans-Hazelaar*

19 #2027-Prognostic impact of stem cell marker CD133 in 61 glioblastoma patients treated with concomitant chemoradiation: A prospective study.

*Philippe Metellus*

20 #2028-CD133 expression in glioblastoma recurring after radiation therapy.

*Tonia Cenci*

21 #2029-Prognostic value and analytical performance (reproducibility) of Ki67 index in anaplastic oligodendroglial tumors: A translational study of the EORTC Brain Tumor Group.

*Matthias Preusser*

22 #2030-Stereotactic radiosurgery: A new paradigm for melanoma and renal cell carcinoma spine metastases.

*Anu Thiagaragan, MD*

23 #2031-Chemotherapy (CT) alone for epidural spinal cord compression (ESCC) from germ cell tumors (GCT).

*Christian Grommes*

24 #2032-Immunomagnetic platform technology (IMPT) for the diagnosis of leptomeningeal metastasis in solid tumors (LMST).

*Lakshmi Nayak*

- Discussion

*Eric L. Chang, MD*

---

**Session Title:** #242: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** E354b

**Time:** 12:00 PM - 1:00 PM

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

*Razelle Kurzrock, MD*

- Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

*Lesley Seymour, MD, PhD*

1 #2515-Phase I trials of novel molecularly targeted therapies: Should we pay more attention to toxicities occurring after cycle 1?

*Sophie Postel-Vinay*

2 #2516-Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience.

*Dionysios Papadatos-Pastos, MD, MRCP*

3 #2517-An international pooled analysis identifying predictive factors associated with toxicities in phase I trials (Delphi).

*Carlos Alberto Gomez-Roca*

4 #2518-Multi-institutional prognostic factor analysis of patients (pts) enrolled in phase I (Ph I) oncology trials: Can pts selection be improved?

*David Olmos*

5 #2519-Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience.

*Salma M. Alam*

6 #2520-VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints.

*Manish Sharma*

- Discussion

*David J Stewart*

7 #2521-The trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population).

*Michael Jäger*

8 #2522-Phase I PK/PD study of RO5083945 (GA201), the first glycoengineered anti EGFR monoclonal antibody (mAb) with optimized antibody dependent cellular cytotoxicity (ADCC).

*Ben Markman*

9 #2523-Radioimmunotherapy (RIT) with 131I-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial.

*Gianluca Del Conte*

10 #2524-First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiotensin 2.

*Lee S. Rosen*

11 #2525-Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

*Amita Patnaik*

- Discussion

*Ravi Salgia, MD, PhD*

12 #2526-Final reporting of a phase I clinical trial of the oral PPAR-gamma agonist, CS-7017, in patients with advanced malignancies.

*Michael J. Pishvaian*

13 #2527-Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium trial.

*Timothy W. Synold, PharmD*

14 #2528-AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.

*Thomas A. Samuel, MD*

15 #2529-A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.

*Jonathan Wade Goldman*

16 #2530-Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors.

*Craig Peter Carden*

17 #2531-Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

*T.R. Jeffry Evans*

- Discussion

*Lesley Seymour, MD, PhD*

18 #2532-Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy.

*James L. Rubenstein*

19 #2533-A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC).

*Syma Iqbal*

20 #2534-A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P).

*Maysa M. Abu-Khalaf, MD*

21 #2535-A phase I study of gemcitabine, capecitabine, and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies.

*Sujatha Nallapareddy*

22 #2536-A phase I study of aflibercept, pemetrexed (P), and cisplatin (C) in patients with advanced solid tumors.

*Carol A. Townsley*

23 #2537-Targeted cancer therapies: FDA approval overview.

*Patricia Cortazar*

24 #2538-Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.

*John S. Kauh, MD*

- Discussion

*Razelle Kurzrock, MD*

---

**Session Title:** #250: Health Services Research

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S504

**Time:** 12:00 PM - 1:00 PM

- Health Services Research

*Benjamin D. Smith, MD*

- Health Services Research

*Elissa Ozanne, PhD*

1 #6009-Burden of illness estimates of metastatic breast cancer (MBC) in the United States.

*Sonja Sorensen*

2 #6010-Adjuvant endocrine monotherapy with tamoxifen or aromatase inhibitors for postmenopausal women with breast cancer: What is the economic impact of CYP 2D6 testing?

*Tallal Younis*

3 #6011-Comparative effectiveness of screening, surgery, and chemoprevention among BRCA1/2 mutation carriers.

*Victor Grann, MD, MPH*

4 #6012-Therapeutic options for low-risk prostate cancer: A cost-effectiveness analysis.

*Julia H Hayes*

5 #6013-Year one evaluation of regional pay for quality (P4Q) oncology program.

*Jeffrey A. Scott*

6 #6014-Conflicts of interest in economic analyses presented at the American Society of Clinical Oncology Annual Meeting.

*Sekwon Jang*

7 #6015-Does increasing insurance improve outcomes for U.S. cancer patients?

*Jillian K Smith*

- Discussion: Role of cost and comparative effectiveness research in guiding health policy

*Elena B. Elkin, PhD*

8 #6016-Surgeon influence on patient appraisal of ASCO breast cancer quality indicators.

*Sarah T. Hawley, MD, PhD*

9 #6017-The impact of audit and feedback on nodal harvest in colorectal cancer (CRC).

*Geoffrey A. Porter*

10 #6018-Quality of care in non-small cell lung cancer (NSCLC): Findings from the Florida initiative for quality cancer care (FIQCC).

*Tawee Tanvetyanon*

11 #6019-Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma: Evaluating community guideline adherence.

*Nader N Massarweh, MD*

12 #6020-Scientific evidence underlying National Comprehensive Cancer Network Clinical Practice Guidelines.

*Thejaswi K.Poonacha*

- Discussion: Oncology guidelines: adherence and appraisal

*Jennifer Malin*

13 #6021-End of life care for elderly patients with advanced lung cancer in the United States and Ontario.

*K. Robin Yabroff*

14 #6022-Impact of care at NCI-designated Comprehensive Cancer Centers (NCICCCs) on racial differences in prostate cancer-specific survival.

*Can-Lan Sun*

15 #6023-Trends in prostatectomy: Centralization, robotics, and access to care.

*Karyn Beth Stitzenberg*

16 #6024-PSA surveillance in men with localized prostate cancer.

*Debra Nana Yeboa*

17 #6025-Restoration of medical oncology services at Charity Hospital in New Orleans after Hurricane Katrina: A 2-year experience of the Louisiana State University Health Sciences Center (LSUHSC).

*Brian C. Boulmay, MD*

18 #6026-Appropriateness of cardiovascular (CV) care in cancer survivors (CS).

*Winson Y. Cheung*

19 #6027-Estimation of the U.S. rate of neutropenic complications for cancer hospital discharges.

*Mike Dickson*

- Discussion: Patterns of cancer care

*Stephen B. Edge, MD*

20 #6028-Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs).

*Bostjan Seruga*

21 #6029-A compendium of unpublished phase III clinical trials in oncology: Characteristics and impact on clinical practice.

*Vincent Channing Tam, MD, FRCPC*

22 #6030-The assessment of cost and other barriers to patient clinical trial participation in the community setting.

*Douglas Weckstein*

23 #6031-Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials.

*Benoit You*

24 #6032-Influence of nonclinical patient factors on decisions to recommend breast cancer adjuvant chemotherapy.

*Tunghi May Pini, MD, MPH*

25 #6033-Factors associated with decision making for use of adjuvant chemotherapy (AT) in referred patients (pts) with resected high-risk colon cancer (CC).

*Doran Ksienski*

- Discussion: Clinical trials and decision making

*Benjamin Djulbegovic, MD, PhD*

---

**Session Title:** #120: Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention

**Session Type:** Meet the Professor Session

**Date:** Saturday, June 5

**Location:** E451b

**Time:** 1:00 PM - 2:15 PM

- Sonic Hedgehog Pathway Inhibitors for Skin Cancer Prevention

*Aleksandar Sekulic, MD, PhD*

---

**Session Title:** #149: Developmental Therapeutics - Experimental Therapeutics

**Session Type:** Oral Abstract Session

**Date:** Saturday, June 5

**Location:** E Hall D2

**Time:** 1:00 PM - 4:00 PM

- Developmental Therapeutics - Experimental Therapeutics

*Richard H. Wilson, MD*

- Developmental Therapeutics - Experimental Therapeutics

*Michael L. Maitland, MD, PhD*

- #3006-First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma.

*Daniel Shao-Weng Tan, BSc, MBBS*

- #3007-Dual inhibition of IGFR and mTOR pathways.

*Aung Naing, MD, FACP*

- #3008-A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors.

*Serena Di Cosimo*

- #3009-First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity.

*Timothy Anthony Yap*

- Discussion: Drugging the IGF1R/Akt/mTOR signaling network  
*Manuel Hidalgo, MD, PhD*
  - #3010-Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors.  
*Elizabeth Claire Dees, MD*
  - #3011-A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors.  
*Klaus B. Mross*
  - #3012-Phase I, first-in-human study of the centromere-associated protein e (CENP-E) inhibitor GSK923295 in patients with advanced solid tumors (Study CPE107602).  
*Kyle D. Holen*
  - Discussion: Novel agents and targets in mitosis  
*Johann Sebastian De Bono, MD, PhD*
  - #3013-Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer.  
*David S. Mendelson*
  - #3014-A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.  
*Colin D. Weekes, MD, PhD*
- 

**Session Title:** #160: Lymphoma

**Session Type:** Oral Abstract Session

**Date:** Saturday, June 5

**Location:** E354a

**Time:** 1:00 PM - 4:00 PM

- Lymphoma  
*Kenneth Stuart Cohen, MD*
- Lymphoma  
*John Leonard, MD*
- #8004-Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy.

*Gilles A. Salles*

- #8005-Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy.

*Ruth Pettengell*

- Discussion: Role of maintenance therapy in follicular lymphoma

*Richard I. Fisher, MD*

- #8006-Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD.

*Francesca Fiore*

- #8007-Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT).

*Anna Sureda*

- Discussion: Improving outcomes in Hodgkin Lymphoma

*Ralph M. Meyer, MD*

- #8008-Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The g-PCNSL-SG1 randomized phase IV trial.

*Eckhard Thiel*

- #8009-Limited-stage diffuse large B-cell lymphoma (DLBCL) treated with abbreviated systemic therapy and consolidation radiotherapy: Involved field radiotherapy (IFRT) versus involved nodal radiotherapy (INRT≤5cm).

*Belinda A Campbell*

- Discussion: What is the role of radiation in large cell lymphoma?

*Joachim Yahalom, MD*

- #8010-A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma.

*Frédérique Kuhnowski*

- #8011-Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed patients with diffuse large B-cell lymphoma (DLBCL) who are not candidates for high-dose therapy (HDT): A GELA study.

*Taoufik EL Gnaoui*

- #8012-Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.

*Ranjana Advani*

**Session Title:** #162: Melanoma/Skin Cancers

**Session Type:** Oral Abstract Session

**Date:** Saturday, June 5

**Location:** S406 (Vista Room)

**Time:** 1:00 PM - 4:00 PM

- Melanoma/Skin Cancers

*Thomas Gajewski, MD, PhD*

- Melanoma/Skin Cancers

*Tim Eisen, PhD, FRCP*

- #8504-E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma.

*David H. Lawson*

- #8505-Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961.

*Alexander M. Eggermont, MD, PhD*

- #LBA8506-Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial.

*Jean Jacques Grob*

- Discussion

*Michael S. Sabel, MD, FACS*

- #8507-Interleukin-21 (IL-21) has activity in patients (pts) with metastatic melanoma (MM).

*Teresa M. Petrella*

- #8508-First report of a randomized phase II trial of multi-epitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells in patients with metastatic melanoma: An Eastern Cooperative Oncology Group study (E1602).

*Craig L. Slingluff, MD*

- #8509-Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma.

*F. Stephen Hodi, MD*

- Discussion

- #8510-Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: Final results of a phase II multicenter study.

*Eve Maubec*

- #8511-Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma.

*Keith T. Flaherty, MD*

- #LBA8512-A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma.

*James F. Pingpank, MD, FACS*

- Discussion

*Dirk Schadendorf, MD*

---

**Session Title:** #5: A Family's Year with Cancer

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S404

**Time:** 1:15 PM - 2:30 PM

- The Impact of Cancer on Families

*Lidia Schapira, MD*

- A Family's Year with Cancer

*David Treadway, PhD*

- A Family's Year with Cancer

*Kate Treadway, MD*

---

**Session Title:** #46: Evolving Standards of Care in Advanced Renal Cell Carcinoma

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E Hall D1

**Time:** 1:15 PM - 2:30 PM

- Systemic Therapies in Advanced Renal Cell Cancer: Current Status

*Christopher W. Ryan, MD*

- Integration of Nephrectomy in Advanced Renal Cell Cancer Management

*Eric Jonasch, MD*

- Towards Individualizing Therapy in Advanced Renal Cell Cancer

*Primo Lara, MD*

---

**Session Title:** #51: Future Directions in the Management of Endometrial Cancer

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E Arie Crown Theater

**Time:** 1:15 PM - 2:30 PM

- Surgically Staging of Endometrial Cancer: The Controversy Continues

*David E. Cohn, MD*

- Optimizing Adjuvant Therapy in the Treatment of Early Stage Endometrial Cancer Patients

*Carien Creutzberg, MD, PhD*

- Incorporating Novel Biologic Therapies into Endometrial Cancer Treatment

*Gini F. Fleming, MD*

---

**Session Title:** #59: Implementing Clinical Trials: Risks, Benefits, Marketing, and Paying for It All

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E353

**Time:** 1:15 PM - 2:30 PM

- Structuring / Marketing a program for success

*Robin Zon, MD, FACP*

- The critical role of creating a research team

*Gary Irvin Cohen, MD*

- Negotiating a contract - Knowing Cost to effectively budget for pharma trials.

*Dee Anna Smith*

**Session Title:** #60: Improving Access to Clinical Trials

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S100a

**Time:** 1:15 PM - 2:30 PM

- Overcoming barriers to access to cancer care and cancer trial enrollment in minority populations

*Derek Raghavan, MD, PhD*

- Overcoming barriers to clinical trials: Increasing accrual through partnership with community oncologists

*J. Phillip Kuebler, MD, PhD*

- Overcoming barriers to clinical trial accrual in elderly population and patients with co-morbidities

*Hyman Bernard Muss, MD*

**Session Title:** #68: Management of Side Effects of the Treatment of Colorectal Cancer (including eQuestions)

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E354b

**Time:** 1:15 PM - 2:30 PM

- Managing and reducing side effects of pelvic radiation

*Bruce D. Minsky, MD*

- Dermatologic toxicities of targeted therapy in colorectal cancer

*Mario E. Lacouture, MD*

- Management of oxaliplatin-induced neurotoxicity

*Howard S. Hochster, MD*

**Session Title:** #81: New Treatments for Sarcoma in Children, Adolescents, and Young Adults

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S504

**Time:** 1:15 PM - 2:30 PM

- Optimal approaches for achieving local control in children, adolescents, and

- Optimal strategies for controlling metastatic disease in children, adolescents, and young adults with sarcoma

*Douglas S. Hawkins, MD*

- Treatment of childhood, adolescent, and young adult sarcoma. Where do we go from here?

*Stephen X. Skapek, MD*

---

**Session Title:** #100: The Global Burden of Cancer: The Worldwide Challenge of Cancer Control

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S100b

**Time:** 1:15 PM - 2:30 PM

- Causes of preventable cancer in the world: from tobacco to tanning boxes (the expanding list of IARC class I carcinogens)

*Donald M Parkin, MD*

- Tobacco as a cause of worldwide cancer mortality

*Prabhat Jha, MD, D.Phil.*

- Prevention of hepatocellular carcinoma via universal vaccination against hepatitis B

*Mei-Hwei Chang, MD*

---

**Session Title:** #125: Improving Outcomes for Patients with Locally Advanced Lung Cancer

**Session Type:** Clinical Problems in Oncology Session

**Date:** Saturday, June 5

**Location:** E451a

**Time:** 1:15 PM - 2:30 PM

- Surgical Management of Locally Advanced Lung Cancer

*Douglas E. Wood, MD*

- Stage III NSCLC: Does Better Technology = Better Treatment?

*Jeffrey Bogart, MD*

- Systemic Therapy for Locally Advanced NSCLC including the Role of Treatment Post Chemoradiotherapy

*Julie R. Brahmer, MD*

**Session Title:** #219: Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life

**Session Type:** Clinical Science Symposium

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 1:15 PM - 2:45 PM

- Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life

*David Linehan, MD*

- Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life

*Colin D. Weekes, MD, PhD*

- #4000-Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET).

*Patricia Niccoli*

- #4001-A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).

*Alexandria T. Phan, MD*

- #4002-Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker.

*James C. Yao, MD*

- Discussion

*Kjell E. Oberg, MD, PhD*

- #4003-Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial.

*Aaron Vinik, MD, PhD*

- Discussion

*Ian Chau, MD*

**Session Title:** #179: Genitourinary (Nonprostate) Cancer

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** E450a

**Time:** 2:00 PM - 6:00 PM

- Genitourinary (Nonprostate) Cancer

*George Philips, MD, MBBS, MPH*

1 #4520-Association of germline genetic markers in *IL8*, *HIF1A*, *VEGFA*, and *VEGFR2* with treatment response to pazopanib in renal cell carcinoma.

*Howard A Ball*

2 #4521-Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib.

*Karel Eechoute*

3 #4522-Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients.

*Hai T. Tran*

4 #4523-A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.

*Daniel Yick Chin Heng*

5 #4524-The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration.

*Toni K. Choueiri*

6 #4525-Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

*Susan Halabi*

7 #4526-Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma.

*Katherine Margaret Krajewski*

- Discussion: Prediction and prognosis in renal cell carcinoma

*Daniel J. George, MD*

8 #4527-Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure.

*Nizar M. Tannir*

9 #4528^ -A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC).

*Christopher W. Ryan, MD*

10 #4529-Results of a randomized phase II study investigating multi-peptide vaccination with IMA901 in advanced renal cell carcinoma (RCC).

*Carsten Reinhardt, MD, PhD*

- Discussion: Trial design and drug development in RCC

*Ulka N. Vaishampayan, MD*

12 #4531-Results from SWENOTECA V: A population based protocol for seminomatous testicular cancer.

*Torggrim Tandstad*

13 #4532-Risk-adapted management of stage I seminoma: Results of the third Spanish Germ Cell Cancer Group Study.

*Jorge Aparicio*

14 #4533-Cardiovascular risk in long-term testicular cancer survivors.

*Hege Sagstuen Haugnes*

15 #4534-Total treatment burden in stage I seminoma patients.

*Eric Leung*

16 #4535-Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study.

*Peter W. M. Chung*

17 #4536-Evolution of management of testicular seminoma: Population-based outcomes with decreased utilization of active therapies.

*Craig R. Nichols, MD, FACP*

18 #4537-Risk of secondary malignancy in patients with testicular cancer who have received radiation therapy.

*Daniel Lewinshtein*

19 #4538-Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy.

*Alan Horwich*

- Discussion: Germ cell tumors: is radiation under or over-utilized?

*Mary Gospodarowicz, MD*

20 #4539-Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial.

*David I. Quinn, PhD, FRACP, MBBS*

21 #4540-First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit.

*Joaquim Bellmunt*

22 #4541-Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC).

*Noah M. Hahn*

- Discussion: Is there a role for targeted therapy in advanced urothelial cancer?

*Matthew I. Milowsky, MD*

23 #4542-Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer.

*Lamont J Barlow*

24 #4543-Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle-invasive bladder cancer: A prospective randomized trial.

*Savino Mauro Di Stasi*

- Discussion: New therapies in non-muscle invasive urothelial cancer

*Seth P. Lerner, MD*

---

**Session Title:** #192: Tumor Biology

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S103

**Time:** 2:00 PM - 6:00 PM

- Tumor Biology

*Charles D. Lopez, MD, PhD*

- Tumor Biology

*Vered Stearns, MD*

1 #10513-Utilization of genomic signatures for chemotherapy response in prospective clinical studies.

*William Barry*

2 #10514-Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer.

*Silvia Darb-Esfahani*

3 #10515-Gene expression in serial biopsies in locally advanced breast cancer patients who failed to respond to neoadjuvant chemotherapy.

*Mark Jesus M Magbanua*

4 #10516-Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay.

*Christian F. Singer*

5 #10517-Correlation of engraftment, mutation status, and response to chemotherapy in primary tumor xenograft models of NSCLC.

*Tom John*

6 #10518-Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis.

*Charlotte Elberling Almasi*

7 #10519-Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies.

*Coen Bernaards*

8 #10520-Value of a serum proteomic signature in the non-invasive evaluation of lung nodules.

*Chad Victor Pecot*

9 #10521-Use of a nanoparticle-based artificial olfactory system, NaNose, to distinguish malignant from benign pulmonary nodules.

*Nir Peled, MD, PhD*

- Discussion

*Gerold Bepler, MD, PhD*

10 #10522-Association of TS and ERCC1 mRNA expressions with overall survival in patients enrolled in CONFIRM 1 + 2.

*Peter P Grimminger*

11 #10523-Prognostic value of the microtubule stability index (MTSI), defined by the quantitative ratio of MAP-tau to stathmin expression, for outcome in breast cancer.

*Maria T. Baquero*

12 #10524-Association of GRP78 gene polymorphism rs391957 with tumor recurrence in gastric and colon cancer patients.

*Pierre Olivier Bohanes, MD*

13 #10525-Correlation of Snail expression and survival in patients with early-stage triple-negative breast cancer (TNBC).

*Sao Jiralerspong, MD, PhD*

14 #10526-MicroRNA deregulation in peripheral nerve sheath tumor progression.

*Nadege Presneau*

15 #10527-Chemobiological screening for identification of molecular targets for thymic epithelial cancers.

*Oscar D. Cano*

16 #10528-Molecular classification of non-small cell lung cancer using a four protein quantitative assay.

*Valsamo K. Anagnostou, MD*

17 #10529-KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy.

*Kathleen D Danenberg*

18 #10530-Prognostic implications of mutations in the epidermal growth factor receptor (*EGFR*) and *KRAS* among never-smokers with adenocarcinoma of the lung.

*Paul K. Paik*

- Discussion

*David Paul Carbone, MD, PhD*

19 #10531-Comprehensive analysis of expression patterns of insulin-like growth factor and Src pathway in patients with non-small cell lung cancer: Two large, independent series of tissue microarray.

*Jin-Soo Kim, MD*

20 #10532-Immunohistochemical screening of ALK lung cancer with biopsy specimens of advanced lung cancer.

*Keita Kudo*

21 #10533-ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).

*Marileila Varella-Garcia*

22 #10534-A Japanese, nationwide network for the diagnosis of EML4-ALK-positive lung cancer: A joint study of ALCAS and NEJ004.

*Manabu Soda*

23 #10535-A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue.

*Peter V Danenberg*

24 #10536-Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis.

*Victoria Rimkunas*

25 #10537-ALK chromosomal alterations in colon cancer patients.

*Clara Montagut*

- Discussion

*Robert Arthur Kratzke, MD*

**Session Title:** #193: Breast Cancer - Local-Regional and Adjuvant Therapy**Session Type:** General Poster Session**Date:** Saturday, June 5**Location:** S Hall A2**Time:** 2:00 PM - 6:00 PM

1A #536-DEVA: Randomized trial of sequential epirubicin and docetaxel versus epirubicin alone in node-positive postmenopausal early breast cancer (EBC) patients.

*R. Charles Coombes*

1B #537-Long-term results from the neoadjuvant GeparDuo trial: A randomized, multicenter, open phase III study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer (BC).

*Manfred Kaufmann*

1C #538-An epidemiologic study of the effect of adjuvant radiotherapy on 2D tumor characteristics and prognosis of contralateral breast cancer (CBC).

*Maria E.C. Sandberg*

1D #539-The use of Ki67 to predict benefit from adjuvant tamoxifen in node-negative, estrogen receptor-positive patients.

*Rinat Yerushalmi*

1E #540-Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin +/- trastuzumab in patients (pts) with stage II-III and inflammatory breast cancer (IBC).

*George Somlo*

1F #541-Obesity and disease-free survival in patients with nodal-positive early-stage breast cancer: The ADEBAR trial.

*Philip Gm Hepp*

1G #542-Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial.

*Michael Pollak, MD*

1H #543-Predictive value of CD24 ala/val polymorphism for pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

*Frederik Marme*

2A #544-Prospective randomized trial comparing postoperative adjuvant concurrent versus sequential hormonal and different radiation fractionation schedule in breast cancer patients.

*Mohsen Samy Barsoum*

2B #545-Predictive value of a gene signature evaluated in multiple chemotherapy regimens for breast cancer.

*Marcia Fournier*

2C #546-Breast conservation (BCT) for DCIS: A prospective study of how MRI impacts management (MGMT).

*Jennifer Lynn Marti*

2D #547-Trastuzumab versus observation in women with early breast cancer and CK-19 mRNA-positive circulating tumor cells (CTCs): A pilot randomized phase II study.

*Vassilis Georgoulis*

2E #548-The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis.

*Ricardo H. Alvarez*

2F #549-Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms.

*Ian E. Krop*

2G #550-Use of myxovirus resistance 1 (MX1) expression to predict efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and adjuvant trials.

*Fabrice Andre*

2H #551-Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.

*Mark Basik*

3A #552-Final analysis of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment (NST) in early breast cancer (EBC): Japan Clinical Oncology Group Trial (JCOG0306).

*Hirofumi Mukai*

3B #553-Preoperative diagnosis of sentinel lymph node (SLN) metastasis using 3D CT lymphography (CTLG): A new technology for sentinel node navigation.

*Misako Nakagawa*

3C #554-Report of toxicities from the multicenter, randomized NNBC 3-Europe trial: 6xFEC versus 3xFEC & 3xDoc for high-risk node-negative breast cancer patients.

*Christoph Thomssen*

3D #555-The role of beta-blockers and ACE inhibitors in the prevention of trastuzumab-related cardiotoxicity.

*Javier Munoz*

3E #556-Predictive response factors (PRF) in an open, nonrandomized, phase II study of a combination of bevacizumab (BZ) and sequential chemotherapy as preoperative treatment in patients with operable HER2-negative breast cancer (BC).

*Pedro Sanchez Rovira*

3F #557-Comparison of 21-gene recurrence score (RS) in African-American (AA) and caucasian (C) patients with hormone receptor (HR)-positive early-stage breast cancer.

*Kelli M Davis*

3G #558-Effect of dose-dependent interaction between tamoxifen and antidepressants on patient adherence in breast cancer patients.

*Felix W Frueh*

3H #559-BACH: A randomized phase II trial of doxorubicin-cyclophosphamide (AC) versus pegylated liposomal doxorubicin (PLD)-cyclophosphamide-trastuzumab (CCH) followed by paclitaxel-trastuzumab (TH) as adjuvant therapy for HER2-positive breast cancer (BC)-Cardiac safety analysis.

*Daniel Rayson*

4A #560-Gene signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial.

*Sirwan M Hadad, PhD, MBChB*

4B #561-Evaluation of the 70-gene prognosis MammaPrint signature for the prediction of prognosis of breast cancer independently from histologic grade.

*Michael Knauer*

4C #562-Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in NCIC CTG MA.14.

*Judy-Anne W Chapman*

4D #563-Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.

*Hélène Kolesnikov-Gauthier*

4E #564-Comparison of first-course PET scan against fourth-course MRI for early detection of poor responders to neoadjuvant chemotherapy (NAC) for breast cancer (BC).

*Maribel Cotto*

4F #565-Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E.

*Celyne Bueno Hume*

4G #566-Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy.

*Michael J. Hassett, MD, MPH*

4H #567-Five-year results of preoperative concurrent paclitaxel with radiation in locally advanced breast cancer (LABC).

*Silvia Formenti*

5A #568-Prospective study of wide local excision and endocrine therapy without radiotherapy (WORTH) for node-negative, estrogen receptor-positive early breast cancer with negative histologic margins (WORTH trial, Protocol 1): Five-year interim results.

*Reiki Nishimura*

5B #569-Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer.

*Charles Swanton*

5C #570-Cosmetic outcome two and three years after intraoperative radiotherapy compared with external beam radiotherapy for early breast cancer: An objective assessment of patients from a randomized controlled trial.

*Mohammed R. Keshtgar*

5D #571-Cardiovascular safety of adjuvant bevacizumab for breast cancer.

*Erica L. Mayer, MD*

5E #572-Association of gene copy number alterations in formalin-fixed, paraffin-embedded tumors with prognostic molecular and pathologic tumor subtypes in early-stage breast cancer.

*James L. Murray*

5F #573-Primary endocrine therapy for early operable primary breast cancer in elderly women: Survival analysis of a large series from a single institution.

*Waleed Al-Khyatt*

5G #574-Do socioeconomic factors and insurance explain racial/ethnic disparities in receipt of recommended breast cancer care?

*Rachel A. Freedman*

5H #575-Chemotherapy (CT) versus tamoxifen (T) versus chemotherapy plus tamoxifen (CTT) in patients with node-positive (N+), estrogen receptor-positive (ER+) breast cancer (bca): Very late results of an Italian multicentric trial.

*Francesco Boccardo*

6A #576-Randomized phase II trial of preoperative lapatinib versus placebo in HER-2-positive breast cancer.

*Andrea De Censi*

6B #577-Decision analysis: Excision alone versus excision plus radiation therapy for ductal carcinoma in situ.

*Rinaa S. Punglia*

6C #578-Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer.

*Dawn L. Hershman, MD*

6D #579-Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for early-stage breast cancer (ESBC).

*Michelle E. Melisko*

6E #580-Outcomes differences in tumors < 1 cm by age and breast cancer subtype.

*Jennifer Keating Litton*

6F #581-Adjuvant chemotherapy and lymph node irradiation in breast cancer patients with axillary lymph node micrometastases or isolated tumor cells.

*Miriam Gardner*

6G #582-Poly(ADP-ribose) polymerase-1 (PARP-1) expression in patients treated with breast-conserving surgery and radiation therapy (BCS+RT).

*Julie Goswami*

6H #583-Cause-specific and all-cause mortality of HER2-positive, node-negative, T1a and T1b breast cancers.

*Helen K. Chew*

7A #584-Comorbidities' impact on survival after treatment for early breast cancer.

*Lotte Holm Land*

7B #585-MDR1/ABCB1 single nucleotide polymorphism (SNP) as a possible prognostic factor in breast cancer patients receiving docetaxel and doxorubicin neoadjuvant chemotherapy.

*Hee Jun Kim, MD*

7C #586-Correlation between quantitative HER2 protein level and pathologic complete response (pCR) in HER2-positive (+) breast cancer patients (pts) treated with neoadjuvant (NEO) dose-dense (dd) chemotherapy plus trastuzumab.

*Judith Hurley*

7D #587-Do older patients with T1a lesions require sentinel lymph node biopsy?

*Meaghan W O'Malley*

7E #588-Use of sequential FDG-PET/CT to guide extent of axillary lymph node dissection in breast cancer receiving neoadjuvant chemotherapy.

*Bhumsuk Keam, MD*

7F #589-Predictors of pathologic response and correlation with long-term outcomes in a trial of neoadjuvant concurrent paclitaxel radiation in locally advanced breast cancer (LABC).

*Sylvia Adams*

7G #590-The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer.

*Robert C. F. Leonard*

7H #591-Obesity and tumor characteristics in nodal-positive early-stage breast cancer: Results of the German ADEBAR study.

*Ulrich Andergassen*

8A #592-Use of prolyl 3-hydroxylases (P3H) to predict endocrine sensitivity in primary breast cancer.

*Peter Schmid, MD, PhD*

8B #593-Is the difference in reexcision rate of various margin assessment methods due solely to difference in volume excised?

*Candice K. Culpepper*

8C #594-Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041).

*Aman Buzdar*

8D #595-A prospective study to evaluate the role of 2-[18F] fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET), breast magnetic resonance imaging (MRI), and breast ultrasonography in monitoring tumor responses in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy.

*Som Dave Mukherjee*

8E #596-Guideline adherence rates of chemotherapy treatment for breast cancer patients treated in U.S. community oncology practices.

*Kimberly A. Berastrom*

8F #597-The prognostic impact of age in patients with triple-negative breast cancer.

*Cornelia Liedtke*

8G #598-Utility of the vulnerable elders survey for predicting sixth-month functional decline among older patients with newly diagnosed breast cancer.

*Cynthia Owusu*

8H #599-Weight change during adjuvant chemotherapy regimens for breast cancer.

*Rebecca M Speck*

9A #600-Use of PET to assess tumor metabolism and blood flow by tumor subtype in locally advanced breast cancer.

*Susan K Montgomery*

9B #601-Activity of ixabepilone and PARP inhibitors in triple-negative breast cancer (TNBC) based on gene expression.

*Christine E. Horak*

9C #602-Evidence for change in prognostic stratification of breast tumor subtypes.

*Shaheenah S. Dawood*

9D #603-Is short interval mammogram necessary after breast-conservation surgery and radiation treatment in breast cancer patients?

*Richard Val Hymas*

9E #604-Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).

*Ewa Mrozek*

9F #605-What part does sleep disturbance play in post-cancer fatigue? Findings from a prospective cohort study.

*Barbara Kaye Bennett*

9G #606-HER2 testing: A health economics perspective on alternative test strategies.

*James A Lee*

9H #607-Residual cancer burden (RCB) in breast cancer patients treated with taxane and anthracycline-based neoadjuvant chemotherapy: The effect of race.

*Mariana Chavez-Mac Gregor*

10A #608-Expression of forkhead-box protein A1 (FOXA1) as a significant prognostic and predictive marker for ER-positive breast cancer.

*Eriko Tokunaga, MD, PhD*

10B #609-The influence of mammoplasty in axillary lymphatic drainage patterns and sentinel lymph node detection.

*Catherine Bouteille*

10C #610-Effect of neoadjuvant alternating taxane- and anthracycline-based dose-dense regimen for operable breast cancer on prognosis in triple-negative tumors with a complete histological response.

*Jacques Medioni*

10D #611-Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer.

*Robin Lewis Jones*

10E #612-Breast cancer patients access to screening, radiotherapy, and cancer drugs in 18 European, Asian, and Latin American countries.

*Nils Erik Wilking*

10F #613-The impact of the radiotherapy boost in ductal carcinoma in situ.

*Philip Wong*

10G #614-Cost-effectiveness of adjuvant systemic therapy in early-stage breast cancer patients with isolated tumor cells or micrometastases in regional lymph nodes.

*Maaïke De Boer*

10H #615-Use of adjuvant trastuzumab with chemotherapy in women with small, node-negative, HER2-positive breast cancers.

*Heather L. McArthur, MD, MPH*

11A #616-Substituting doxorubicin with nonpegylated liposomal doxorubicin (NPLD) in adjuvant/primary chemotherapy for early breast cancer, impact in cardiac function: A pilot study.

*Neville Davidson*

11B #617-Positron emission tomography (PET) and estrogen receptor (ER) ligand in patients with invasive breast cancer.

*Mary Gemignani*

11F #618-Notch and jak/STAT signaling pathways in breast carcinoma of luminal and basal/triple-negative immunophenotypes.

*Encarna Adrover*

11G #619-Germline single nucleotide polymorphisms (SNPs) in XRCC3, XRCC1, and XPD, and survival outcomes after adjuvant chemotherapy (CT) in early breast cancer (EBC) patients (pts).

*Elena Castro*

11H #620-Neoadjuvant chemotherapy (NCT) in operable HR-positive and TN breast cancer (BC): A randomized study comparing standard schedule to response-adapted sequence.

*Christelle Jouannaud*

12A #621-Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients.

*Valentina Guarneri*

12B #622-Meta-analysis on the impact of post-mastectomy radiotherapy on breast reconstruction outcome.

*Mitchel J Barry*

12F #623-Correlation of 18FDG PET-CT with SPET-CT lymphoscintigraphy to guide surgical management of the axilla in patients with T2 or T3 breast cancer.

*Claude Soler*

12G #624-Early operable primary breast cancer in elderly (age 70 and older) women (EPC): Changing pattern of management and clinical outcome over 36 years.

*Simon J. Johnston*

12H #625-High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy.

*Amelia Bruce Zelnak*

13A #626-Aromatase inhibitor and tamoxifen's impact on breast cancer recurrence among survivors in a large HMO.

*Reina Haque*

13B #627-Correlation of levels of serum 25-hydroxyvitamin D (25-OHD) and lymph node positivity in operable breast cancer: A Turkish Oncology Group study.

*Mustafa Kadri Altundag*

13C #628-Role of progesterone receptor status (PR) as predictive factor of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer patients.

*Jose Manuel Perez-Garcia*

13D #629-A phase III study of increasing doses of epirubicin (E) and docetaxel (D) plus pegfilgrastim (Pegf) for locally advanced (LABC) or inflammatory breast cancer (IBC): NCIC CTG MA.22.

*Maureen E. Trudeau*

13E #630-Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials.

*Jens Huober*

13F #631-Trends in the use of implantable partial breast radiation therapy for early-stage breast cancer in the United States.

*Andrea M Abbott*

13G #632-Clinical relevance of TNM staging system according to breast cancer (BC) subtypes.

*Yeon Hee Park*

13H #633-Can tumor biomarkers predict response to neoadjuvant anthracycline/taxane chemotherapy in LABC?

*John Frederick Hilton*

14A #634-Prognostic value of CD44s is prognostic in the NCI randomized trial on breast conservation with 25-year follow-up.

*Tu D Dan*

14B #635-Predictive role of [18F]FDG-PET early evaluation in patients (pts) undergoing preoperative chemotherapy (PCT) for breast cancer (BC).

*Andrea Martoni*

14C #636-The expression patterns of STAT-3, phosphorylated STAT-3, P38 MAP-kinase, and phosphorylated P38 MAP-kinase in triple-negative breast cancers and their prognostic significance.

*Emel Yaman*

14D #637-Use of trastuzumab associated with cisplatin and vinorelbine followed by docetaxel as a neoadjuvant regimen for patients with HER2-positive breast cancer.

*Guido Carillio*

14E #638-Twenty-year results of alternating radiotherapy and chemotherapy in nonmetastatic inflammatory breast cancer.

*Eduardo Lima Pessoa*

14F #639-Early therapeutic intervention based on blood tumor markers (TMs) in patients with primary breast cancer (PBC).

*John Forsyth Russell Robertson*

14G #640-Independent comparison of three mathematical models for predicting the risk of additional nodal metastases after positive sentinel lymph node biopsy in early breast cancer.

*Yasser Z Moghaddam, MD*

14H #641-Composite and component expression score correlations in ER-positive breast cancer.

*Alice M. Wang, MS*

15A #642-Comparison of a novel molecular assay with touch imprint and permanent histology of sentinel lymph nodes in early-stage breast cancer.

*Sukamal Saha*

15C #644-Effect of preoperative concomitant chemoradiotherapy in chemotherapy-refractory breast cancer on feasibility of curative surgery and pathologic tumor response.

*Ismael Ghorbel*

15D #645-Dose-dense chemotherapy in nonmetastatic breast cancer patients: A systematic review and meta-analysis.

*Luisa Bonilla, Bsc, MD*

15E #646-MicroRNA expression to classify breast cancer and predict relapse.

*Jeannine De La Cruz*

15F #647-Influence of primary systemic therapy on minimal residual disease in primary breast cancer.

*Bahriye Aktas*

15G #648-Neoadjuvant chemotherapy (NCT) in 466 patients for operable breast cancer : Predictive factors for pathological response.

*Catherine Abrial*

15H #649-Indocyanine green fluorescence imaging system for sentinel lymph node biopsy in early breast cancer patients.

*Hajime Abe, MD, PhD*

16A #650-Management and outcome of HER2-positive breast cancer treated with and without adjuvant trastuzumab: The Imperial College London experience.

*Deep Shah*

16B #651-Long-term results of a phase II trial of preoperative concurrent radiochemotherapy for breast cancers.

*Marc A Bollet*

16C #652-Phase II study of the combination of gemcitabine plus carboplatin as neoadjuvant treatment in locally advanced breast cancer.

*Vichien Srimuninnimit*

16D #653-Clinicopathologic, molecular subtype, and survival prognostic features in premenopausal breast cancer patients by age at diagnosis.

*Carlos Vallejos Sologuren*

16E #654-Outcome of patients with nonmetastatic breast cancer receiving nitrogen-containing bisphosphonates: A comparative analysis from the Metropolitan Detroit Cancer Surveillance System (MDCSS).

*Zeina A. Nahleh*

16F #655-Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: Therapeutic versus preemptive use of lamivudine.

*Byeong Seok Sohn, MD, MSc*

16G #656-Updated survival-based analysis using inverse probability of censoring weighted analysis (IPCW) to estimate the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer.

*Jonathan Karnon*

16H #657-Breast carcinoma with amplified HER2: A gene expression signature specific for trastuzumab resistance and poor prognosis.

*Thaer Khoury*

17A #658-An advanced computerized decision support technology to support breast multidisciplinary meetings.

*Vivek Patkar*

17B #659-Effect of trastuzumab on antibody-dependent cellular cytotoxicity (ADCC) in HER2 nonamplified (non-amp) breast cancer (BC) cells.

*Denis M Collins*

17C #660-The influence of the 21-gene recurrence score assay on decision-making about adjuvant chemotherapy in stage I-II estrogen receptor-positive breast cancer: Experience at a single center with a uniform treatment policy.

*David Barry Geffen*

17D #661-The prognostic impact of SATB1 gene expression is confined to ER-positive breast cancer.

*Loreta Mavrova*

17E #662-Differential response from neoadjuvant chemotherapy across breast cancer subtypes.

*Hiromitsu Jinno*

17F #663-Local effects of tamoxifen versus aromatase inhibitors (AI) on breast tissue: A longitudinal dynamic contrast enhanced (DCE) breast MRI cohort study.

*Christiane K. Kuhl*

17G #664-Microscopic disease after neoadjuvant therapy in inflammatory breast cancer.

*Ashutosh Lodhi*

17H #665-Efficacy of capecitabine (C)-based therapy in patients with first-line metastatic breast cancer (MBC) previously treated with adjuvant anthracyclines and taxanes.

*Friederike Siedentopf*

18A #666-Timing of genetic testing relative to breast cancer surgery.

*Julia R Trosman*

18B #667-Assessment of concomitant versus sequential aromatase inhibitor with radiotherapy for postmenopausal women with early-stage breast cancer.

*Nasser Mohamed Abd El-Bary*

18C #668-HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit.

*Sekhar Marla*

18D #669-The effects of oncotype DX recurrence scores on chemotherapy receipt in a multi-institutional breast cancer cohort.

*Foluso Olabisi Ademuyiwa*

18E #670-A multicenter study to determine the optimum duration of neoadjuvant letrozole on tumor regression to permit breast-conserving surgery: Final analyses.

*Robert Carpenter*

18F #671-Nasal septum perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer?

*Audrey Mailliez*

18G #672-Observational GHEA study: Adjuvant trastuzumab treatment of HER2-positive breast carcinomas in the Italian clinical setting compared to HERA trial.

*Manuela Campiglio*

18H #673-Association between c-myc amplification and other biologic features and prognosis in primary breast cancer.

*Elisabetta Pietri*

19A #674-Indocyanine green (ICG) fluorescence imaging versus radioactive colloid for sentinel lymph node identification in patients with breast cancer.

*Nobumi Tagaya, MD, PhD*

19B #675-Predictive factors of ductal spreading in preoperative breast cancer patients.

*Kazufumi Hisamatsu*

19C #676-Lymphatic and vascular invasion patterns in triple-negative breast cancer.

*Sebnem Yaman*

19D #677-Progesteron receptor status as a predictor of progression-free survival and overall survival in patients with early breast cancer.

*Tiziana Latiano*

19E #678-Comparative evaluation of two methods of chemotherapy dose calculation according to body surface area and body mass index in obese females with breast cancer.

*Tamer Refaat*

19F #679-The effect of aspirin therapy on circulating vascular endothelial growth factor (VEGF) levels in tamoxifen-treated women.

*Chris E. Holmes*

19G #680-Long-term outcome of phase II study of biweekly dose-dense AC followed by weekly paclitaxel and carboplatin and trastuzumab (TC &plusmn; H) based on HER2 status in large and inflammatory breast cancer (BC).

*Rita S. Mehta*

19H #681-A multicenter phase II study of primary systemic therapy epirubicin/cyclophosphamide followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer.

*Toshiaki Saeki*

20B #683-Pathologic response rate for high-risk operable breast cancer after TNCF semi-intensive neoadjuvant chemotherapy: Updated data with long-term results.

*Xavier Durando*

20C #684-First-line patterns of care and outcomes of HER2-positive breast cancer patients who progressed after receiving adjuvant trastuzumab in the outpatient community setting.

*Stephen K. Gruschkus*

20D #685-Phase IB study of primary chemotherapy with paclitaxel, gemcitabine, and sunitinib in patients with HER2-negative stage II/III breast cancer.

*Keun Seok Lee*

- Breast Cancer - Local-Regional and Adjuvant Therapy

*ken cho*

**Session Title:** #194: Breast Cancer - Metastatic

**Session Type:** General Poster Session

**Date:** Saturday, June 5

**Location:** S Hall A2

**Time:** 2:00 PM - 6:00 PM

21A #1032-Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guideline (GL) drug therapy recommendations for metastatic breast cancer: An analysis from the commercial managed care claims database PharMetrics (PM).

*Eva M. Lepisto*

21B #1033-Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line therapy.

*Mario Giuliano, MD*

21C #1034-Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer.

*Monica Arnedos, MD*

21D #1035-Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET+LAP) versus anastrozole plus trastuzumab (ANA+TZ) as first-line treatment for postmenopausal women with HER2+ and HR+ metastatic breast cancer (MBC) from the U.K. National Health Service (NHS) perspective.

*Valerie Hastings*

21E #1036-Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy.

*Sunil S. Badve*

21F #1037-Early detection of recurrent breast cancer using metabolite profiling.

*Vincent Asiago*

21G #1038-A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC).

*Karen L. Tedesco, MD*

21H #1039-Use of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers.

*Libero Santarpia*

22A #1040-Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results.

*Hope S. Rugo, MD*

22B #1041^--Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in patients (pts) with heavily pretreated HER2-positive metastatic breast cancer (MBC): Pooled data of extension cohorts of phase Ib/II studies.

*Guy H M Jerusalem, MD, PhD*

22C #1042-Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer.

*David Tabagari*

22D #1043-Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis.

*V. Calvo*

22E #1044-Use of fresh assessment of tumor-initiating cells in pleural fluid of breast cancer patients to predict overall survival.

*Wendy A. Woodward*

22F #1045-Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT).

*Federica Cuppone*

22G #1046-Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer.

*Francisco J. Esteva*

22H #1047-High-throughput technologies to personalize medical treatment in patients with metastatic breast cancer.

*Roberta Wolp-Diniz*

23A #1048^ -Biomarkers as potential predictors of response to treatment with motesanib or bevacizumab in combination with paclitaxel (P) in patients (pts) with locally recurrent or advanced metastatic breast cancer (MBC).

*Scott D. Patterson, BSc, PhD*

23B #1049-Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L) in combination with docetaxel (D) and trastuzumab (T) in untreated HER2-overexpressing (HER+) metastatic breast cancer (MBC).

*Veronique Dieras*

23C #1050-Use of serum uPA change to predict PFS and overall survival in first-line trastuzumab-treated breast cancer.

*Hui Ying Hou*

23D #1051-Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048).

*Vicente Valero*

23E #1052-Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy.

*Andrew M. Wardley*

23F #1053-Association of receptor activator of NF-kb (RANK) expression with bone metastasis in breast carcinomas.

*Daniele Santini*

23G #1054-A double-blind, randomized, prospective, phase II trial of capecitabine (Cap) plus enzastaurin (Enz) versus cap plus placebo in patients (pts) with advanced breast cancer (BrCa) and prior anthracycline and taxane treatment.

*Mark Clemons*

23H #1055-Correlations between efficacy and early changes in biomarkers in a metastatic breast cancer (mBC) clinical trial with sunitinib malate.

*Kiana Keyvanjah*

24A #1056-Candidate predictive biomarkers of cetuximab benefit in triple-negative breast cancer.

*Shirin Khambata-Ford*

24B #1057-Risk of renal failure associated with IV bisphosphonate use in patients with metastatic breast cancer.

*Wendy J Langeberg*

24C #1058-Age-specific trends of survival in metastatic breast cancer: Data from a population-based cancer registry in Stockholm, Sweden.

*Theodoros Foukakis*

24D #1059-Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer.

*Alessandra Fabi*

24E #1060-Safety and efficacy of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast.

*Palma Fedele*

24F #1061-Long-term effect of fulvestrant on signaling elements in breast cancer.

*Amit Agrawal*

24G #1062-Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results.

*Minish Jain*

24H #1063-Risk factors for central nervous system (CNS) metastases in patients with stage I-III breast cancer.

*Silvia P. Neciosup*

25A #1064-Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC).

*Robert Griffiths*

25B #1065-BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies.

*Martin H. Schuler*

25F #1066-Pertuzumab and trastuzumab: Exploratory biomarker correlations with clinical benefit in patients with metastatic HER2-positive breast cancer.

*Javier Cortes*

25G #1067-Phase I/II study of sunitinib (SU) in combination with metronomic dosing of cyclophosphamide (C) and methotrexate (M) in patients (pts) with metastatic breast cancer (MBC).

*Amy Jo Chien*

25H #1068-Free methylated DNA in association of clinical signs and circulating blood tumor cells in patients with breast cancer.

*Christiane Matuschek*

26A #1069-Survival benefit of neck dissection for patients with breast cancer with supraclavicular lymph node metastasis.

*Shin-Cheh Chen, MD*

26B #1070-Incorporation of a comprehensive geriatric assessment (CGA) into a randomized phase III trial for metastatic breast cancer (MBC): The PELICAN study.

*Maike De Wit*

26F #1071-The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer.

*Tae-Yong Kim*

26G #1072-Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy.

*Katharina Gunzer*

26H #1073-Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC).

*William John Gradishar*

27A #1074-A phase II study of medroxyprogesterone acetate (MPA) in patients (pts) with hormone receptor-negative (HR-) metastatic breast cancer (MBC): Translational Breast Cancer Research Consortium trial 007.

*LaTrice G Vaughn*

27B #1075-Breast cancer metastasis gene signature: The search for the holy grail.

*Rachel E. Ellsworth*

27C #1076-Effect of the novel oncomir MiR-301 on tumor proliferation and invasion in human breast cancer.

*W. SHI*

27D #1077-Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.

*Lubos B. Petruzelka*

27E #1078-Genetic signature of breast cancer with lymphangitic spread to the chest wall: Results from a randomized phase II study combining bevacizumab with oral vinorelbine plus capecitabine (BEVIX).

*Giuseppe Curigliano, MD, PhD*

27F #1079-Primary tumor tissue levels of TIMP-1 and outcome following chemotherapy with docetaxel monotherapy or docetaxel in combination with gemcitabine in patients with locally advanced or metastatic breast cancer.

*Charlotte Levin Tykjær Jørgensen*

27G #1080-Treatment and outcome of metastatic HER2-positive breast cancer relapsing post adjuvant trastuzumab exposure.

*Jonathan Krell*

27H #1081-Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer.

*Hiroji Iwata*

28A #1082-Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: A monoinstitutional experience.

*Simon Spazzapan*

28B #1083-Management of hand-foot skin reaction (HFSR)/hand-foot syndrome (HFS) in SOLTI-0701: A double-blind, randomized phase IIb study comparing sorafenib (SOR) versus placebo (PL) in combination with capecitabine (CAP) in patients (pts) with advanced breast cancer (BC).

*Patricia Gomez*

28C #1084-Do experts agree on how to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research.

*Everardo D. Saad*

28D #1085-Interim safety data on the ZICE trial: A randomized phase III, open-label, multicenter, parallel group clinical trial to evaluate and compare the efficacy, safety profile, and tolerability of oral ibandronate versus intravenous zoledronate in the treatment of patients with breast cancer with bone metastases.

*Peter J. Barrett-Lee*

28E #1086-Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC).

*Tiffany A. Traina*

28F #1087- $^{16}\alpha$ ; - $^{18}\text{F}$ fluoro- $^{17}\beta$ -estradiol (FES)-PET to detect ER-positive tumor lesions in patients with breast cancer with a diagnostic dilemma.

*Michel van Kruchten, MD, MSc*

28G #1088-HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast cancer.

*Sae-Won Han*

28H #1089-Combination with zoledronic acid (ZA) and sunitinib (SU) to reduce severity of osteolytic lesions in bone metastases.

*Christian Schem*

29A #1090-Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC).

*Isabel Blancas*

29B #1091-Risk of gastrointestinal perforation in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis.

*N. Ramirez*

29C #1092-Characteristics of triple-negative metastatic breast cancer among older adults: A population-based analysis.

*Ilene H. Zuckerman*

30A #1093-Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer.

*Cristiano Ferrario*

30B #1094-Circulating tumor cells (CTCs) and association with survival in molecular subtypes (MST) of metastatic breast cancer (MBC).

*Mark L. Graham, MD*

30C #1095-Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE).

*Mansoor N. Saleh*

31A #1096-Kinetic analysis of breast tumor decay and growth following ixabepilone plus capecitabine (IXA + CAP) versus capecitabine alone (CAP) to discern whether the superiority of the combination is a result of slower growth, enhanced tumor cell kill, or both.

*Antonio Tito Fojo*

31B #1097-A phase II cross-over study of docetaxel versus vinorelbine in anthracycline-resistant, advanced breast cancer.

*Constantine C. Alifrangis*

31C #1098-Fulvestrant (F) as first-line palliative treatment for hormone receptor (HR)-positive metastatic breast cancer.

*Rupert Bartsch*

32A #1099-Analysis of truncated HER2 expression and activation in breast cancer.

*Sharat Singh*

32B #1100-Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Preliminary results report of a phase II trial.

*Zhonghua Wang*

32C #1101-Prediction of response in advanced breast cancer (ABC) patients who received trastuzumab-paclitaxel (TP): HER2 FISH ratio, expression of class III beta tubulin (bTubIII), and immunoglobulin G fragment C receptor (FCGR) polymorphisms.

*Jung Ryun Ahn*

33A #1102-Serum-transforming growth factor- $\alpha$ ; (TGF- $\alpha$ ;) and response to lapatinib plus capecitabine in HER2-positive (HER2+) metastatic breast cancer (MBC).

*Jiyoung Rhee*

33B #1103-Effect of surgical treatment of primary tumor on outcome in stage IV breast cancer.

*Matthew Richard Bower*

33C #1104-Concordance to National Comprehensive Cancer Network (NCCN) clinical practice guidelines (GL) for imaging work-up of patients with metastatic breast cancer: An analysis from the commercial managed care claims PharMetrics (PM) and SEER/Medicare (SM) databases.

*Diane L. McNally*

34A #1105-Serum markers to monitor response to zoledronic acid in patients with bone metastases from breast cancer.

*Laura Mercatali*

34B #1106-Correlation of serum leptin level and waist-to-hip ratio (WHR) with overall survival of patients with metastatic breast cancer (MBC) treated with aromatase inhibitors (AIs).

*Mehmet Artac*

34C #1107-Quality-of-life outcomes of patients with breast cancer in an integrative cancer treatment setting.

*Edgar Donald Staren*

35A #1108-Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience.

*Paola Papaldo*

35B #1109-Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC).

*Erika Paige Hamilton*

35C #1110-Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.

*Rita Mukhtar*

35D #1111-Taiwanese patients with breast cancer with brain metastasis (BM) enrolled in the Lapatinib Expanded Access Program (LEAP).

*Chiun-Sheng Huang*

35E #1112-Low cardiotoxicity of nonpegylated liposomal doxorubicin (NPLD) in patients (pts) with metastatic breast cancer (MBC) previously exposed to 360 mg/m<sup>2</sup> of doxorubicin (D).

*Eva Muñoz*

35F #1113-Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).

*Víctor Freixinos*

35G #1114-A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase IIb study evaluating sorafenib (SOR) with paclitaxel (PAC) in patients (pts) with advanced breast cancer (BC).

*Tarini Prasad Sahoo*

35H #1115-A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.

*Nancy Walker Peacock*

36A #1116-A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC).

*Dimitrios Mavroudis*

36B #1117-Comparison of hormone receptor and HER2 status in resected brain metastases and primary breast cancer.

*Zorica Tomasevic, MD, PhD*

36C #1118-Gemcitabine plus cisplatin in pretreated metastatic breast cancer.

*Glaci L. Moura*

36D #1119-Cardiac safety of nonpegylated liposomal doxorubicin in patients with advanced breast cancer treated with myocet plus vinorelbine or myocet plus cyclophosphamide in a randomized phase II trial.

*Vito Lorusso*

36E #1120-Underuse of anthracyclines in women with HER2-positive advanced breast cancer.

*Valentina Rossi*

36F #1121-Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).

*Norikazu Masuda*

36G #1122-Lack of differences in nephrotoxicity of intravenous bisphosphonates in metastatic breast cancer.

*Doerte W. Luedders*

36H #1123-Pathological characteristics and prognosis of a cohort of 74 patients (pts) with breast cancer (BC) with neoplastic meningitis (NM).

*Nuria Kotecki*

37A #1124-Predictive factors for the severity of congestive heart failure after an epirubicin-based treatment for metastatic breast cancer.

*Marianne Ryberg*

37B #1125-Gemcitabine plus cisplatin in patients with heavily pretreated advanced breast cancer with brain metastases.

*Vera A. Gorbunova*

37C #1126-Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.

*Istvan Lang*

37D #1127-An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update.

*Christine B. Brezden*

37E #1128-Safety and efficacy of metronomic nonpegylated liposomal doxorubicin in heavily pretreated advanced breast cancer.

*Luis Manso*

37F #1129-Concomitant gemcitabine, cisplatin, anastrozole, and zoledronic acid in HER2-negative metastatic breast cancer in postmenopausal women.

*Shaharyar Ahmed*

37G #1130-Impact of BMI on clinical outcome of HER2-positive breast cancer.

*Veronica Parolin*

37H #1131-Recurrence and survival after pulmonary metastasis in triple-negative breast cancer.

*Vijaya K. Gadiyaram*

38A #1132-Factors associated with the choice of taxane monotherapy or combination in the management of advanced breast cancer: Results of an international observational study.

*Celaletdin Camci*

38B #1133-Vinorelbine metronomic plus bevacizumab as salvage therapy for patients with metastatic breast cancer (MBC): A multicenter phase II study.

*Emmanuel S. Saloustros*

38C #1134-Changes in cancer tissue induced by treatment with bevacizumab in metastatic breast cancer.

*Georgios Kesisis*

38D #1135-Selective internal radiation therapy (SIRT) for treatment of patients with breast cancer with metastatic liver disease.

*Marlies Michl*

38E #1136-After HERA trial: Safety and activity of trastuzumab plus chemotherapy as first-line therapy for patients with breast cancer previously treated with trastuzumab in adjuvant setting—A single-institution experience.

*Giuseppa Scandurra*

38F #1137-Prospective evaluation of megestrol acetate after aromatase inhibitor failure in advanced endocrine responsive breast cancer: Preliminary results.

*Jose Bines, MD*

38G #1138-Biweekly liposomal pegylated doxorubicin in elderly women with advanced breast cancer: A prospective multicenter trial focusing on tolerability and cardiotoxicity.

*Umberto Basso*

38H #1139-Capecitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC).

*Arlene Chan*

39A #1140-CD4 levels as a prognostic marker for metastatic breast cancer.

*Helen Jane Boyle*

39B #1141-Long-term progression-free survival (PFS) in patients with metastatic breast cancer (BC) treated with tandem autologous followed by allogeneic stem cell transplantation (SCT).

*Cornelia Becker*

39F #1142-Midkine in the plasma as a novel breast cancer marker.

*Yutaka Yamamoto, MD, PhD*

39G #1143-Multicentric, observational, transversal study to describe the clinical profile of patients with metastatic breast cancer (MBC) treated with first-line bevacizumab (TRANSBREAST): Preliminary results.

*María Guirado-Risueño*

39H #1144-Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer.

*Marion Kiechle*

40A #1145-Lapatinib plus capecitabine in highly pretreated HER2-positive metastatic breast cancer: A single-institution experience.

*Diana Crivellari*

40B #1146-Trastuzumab (T) treatment beyond progression in metastatic breast cancer (MBC): Patterns of care in Swiss clinical practice.

*Beat Thurlimann*

40F #1147-Increased mean corpuscular volume of erythrocytes with capecitabine treatment in metastatic breast cancer patients: A marker of clinical benefit?

*Sercan Kadri Aksoy*

40G #1148-Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis.

*Rachel Borson*

40H #1149-Comparison of dual-probe CISH with FISH in the determination of HER2/chromosome 17 for patients with breast cancer in China.

*Guoping Ren*

41A #1150-HER2 as a prognostic factor in metastatic breast cancer treated with taxanes.

*Eileen Parkes*

41B #1151-Comparative morphometric analysis of breast-circulating tumor cells and their corresponding solid tumor cytology: A case study.

*Ethan Daliere Schram*

41C #1152-Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC).

*Berta Alves Sousa*

41D #1153-Prospective evaluation of serum tissue inhibitor of metalloproteinase-1 (TIMP-1) and carbonic anhydrase IX (CAIX) in correlation to circulating tumor cells in patients with metastatic breast cancer.

*Tanja N. Fehm*

41E #1154-Phase I study of lapatinib (L) in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer.

*Nancy U. Lin, MD*

41F #1155-Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC).

*Giulio Metro*

41G #1156-Dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (pts) with metastatic breast carcinoma (MBC): A phase I/II study.

*Monica Nancy Fornier*

41H #1157-Clinical characteristics, univariate, and multivariate Cox model analysis of long-term (> 3 years) survivors of stage IV metastatic breast cancer treated on phase II or III North Central Cancer Treatment Group (NCCTG) trials.

*Tejal Amar Patel*

**Session Title:** #202: Gynecologic Cancer**Session Type:** General Poster Session**Date:** Saturday, June 5**Location:** S Hall A2**Time:** 2:00 PM - 6:00 PM

45A #5034-Use of 99mTc-EC20 (a folate-targeted imaging agent) to predict response to therapy with EC145 (folate-targeted therapy) in advanced ovarian cancer.

*James Thomas Symanowski*

45B #5035-Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive platinum resistant ovarian cancer.

*Guenter Emons, MD, PhD*

45C #5036-Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.

*Paul Sabbatini*

45D #5037-Tolerability and pharmacokinetics of intraperitoneal carboplatin and paclitaxel with intravenous bevacizumab.

*Carolyn N. Krasner*

45E #5038-A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California cancer Phase II Consortia.

*Raimundo Correa*

45F #5039-Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: Results from a phase II study.

*Radoslav Chekerov*

45G #5040-The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin.

*Michele De Tursi*

45H #5041-Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly ADP-ribose polymerase inhibitor (PARPi), in patients with *BRCA1/2*-deficient ovarian cancer (BDOC).

*Joo Ern Ang*

46A #5042-Exposure-response relationships of AMG 386 in combination with

46B #5043-Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations.

*Tamar Safra*

46C #5044-Health-related quality of life (HRQL) and progression-free survival (PFS) in patients with recurrent ovarian cancer: Results from the CALYPSO trial.

*Michael Brundage*

46D #5045-Safety and tolerability of a novel IL-12 gene therapeutic administered in combination with carboplatin/docetaxel in patients with recurrent ovarian cancer.

*Kursheed Anwar*

46E #5046-Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG).

*Bradley J. Monk*

46F #5047-Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer: Update of Japan Clinical Oncology Group (JCOG) protocol 0102.

*Noriyuki Katsumata*

46G #5048-Prognostic role of lymph node status in primary advanced ovarian cancer after complete resection or residual disease less than 1 cm: Results of a meta-analysis of the AGO-OVAR meta-database.

*Philipp Harter*

46H #5049-Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer.

*Robert M Wenham*

47A #5050-Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors.

*Antonella Perotti*

47B #5051-Intraperitoneal mitoxantrone in the treatment of recurrent ascites from progressive epithelial ovarian cancer.

*Marco Marinaccio*

47C #5052-The impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: A retrospective Japan clear cell carcinoma study.

*Masashi Takano*

47D #5053-How does 18f-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer?

*Fatih Selcukbiricik*

47E #5054-Laparoscopic hysterectomy versus abdominal hysterectomy in early-stage endometrial cancer.

*Marian JE Mourits*

47F #5055-ERCC1 status in patients with locally advanced cervical cancer treated with RT or CRT: A multicenter clinicopathologic analysis.

*Corinne M Doll*

47G #5056-The combination of [18f]fluorodeoxy-glucose and 16alpha-[18f]fluoro-17beta-estradiol positron emission tomography for identifying leiomyosarcoma in uterine smooth muscle tumors.

*Yoshio Yoshida*

47H #5057-Low-grade serous primary peritoneal carcinoma.

*David Marc Gershenson*

48A #5058-Significance of the hedgehog (Hh) pathway in ovarian cancer xenograft growth.

*Bo R Rueda*

48B #5059-A phase I dose escalation study of AGS-8M4 (ASP6183), an anti-AGS-8 fully human antibody, in advanced ovarian cancer.

*Deborah Kay Armstrong*

48C #5060-Trabectedin (Tr) as single agent in relapsed ovarian cancer (ROC) patients (pts) with a platinum-free interval (PFI) of 6 to 12 months.

*JM del Campo*

48D #5061-A novel proteomics biomarker panel as a diagnostic tool for patients with ovarian cancer.

*Claus Kim Hogdall*

48E #5062-New aspects in the treatment of cervical cancer complicated by pregnancy: Laparoscopic nodal evaluation before oncologic treatment delay.

*Giovanni Favero*

48F #5063-Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: Single or combination chemotherapy?

*Gerard Adams*

48G #5064-Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).

*Franco Muggia*

48H #5065-Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas.

*Konstantin J Dedes*

49A #5066-Development of a gene expression-based test for the detection of endometrial cancer in uterine aspirates.

*Elisabet Rosell*

49B #5067-Concurrent weekly cisplatin versus gemcitabine with radiation in advanced carcinoma cervix: A study on 120 patients.

*Dipti Rani Samanta*

49D #5069-Prognostic role of dendritic cells and T lymphocytes in the clinical outcomes of stage III ovarian cancer.

*Wei Ding*

49E #5070-The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.

*Naveen Vasudev*

49F #5071-Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A planned 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR).

*Werner Meier*

49G #5072-Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer.

*Limor Helpman*

49H #5073-Characteristics and outcomes of pharmaceutical versus nonpharmaceutical affiliated phase III clinical trials on targeted agents for cancer therapy.

*Katherine Fuh*

50A #5074-Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines.

*Keiko Shoji, MD*

50B #5075-The association between quality of life and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group study.

*Vivian E. Von Gruenigen*

50C #5076-Immunohistochemical expression of ER and PR and outcomes in patients with newly diagnosed uterine leiomyosarcoma.

*Mario M. Leitao*

50D #5077-CA125 response to bevacizumab in recurrent ovarian cancer.

*Roisin Eilish O'Cearbhaill*

50E #5078-Angiogenesis-related gene profile to predict outcome to multimodal therapy in advanced ovarian carcinoma.

*Jorge Barriuso*

50F #5079-Expression of tumor-associated antigen c-terminal binding protein-2 in epithelial ovarian tumors and effect on response to HDAC inhibitors in vitro.

*Lisa M Barroilhet*

50G #5080-The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer: Results from the CALYPSO study.

*Robert John Simes*

50H #5081-Clinical trials of WT1 peptide vaccine to gynecologic malignancies that are resistant to conventional therapies.

*Takashi Miyatake, Dr*

51A #5082-Time to platinum resistance (TTPR) as a novel surrogate endpoint for trials in ovarian cancer.

*Ilya Pokataev*

51B #5083-Sequential angiogenic blockade for the treatment of recurrent ovarian cancer.

*Ursula Matulonis*

51C #5084-Interval from neoadjuvant chemotherapy to interval debulking surgery in advanced ovarian cancer: Is this a prognostic indicator?

*Roopa Hariprasad*

51D #5085-Associations between age and quality of life in advanced ovarian cancer.

*Alexi A. Wright*

51E #5086-Effects of treatment by temsirolimus on patients with clear cell carcinoma of the ovary.

*Yoshihiro Kikuchi*

51F #5087-Regulation of proliferation in endometrial carcinoma cell line by the epidermal growth factor receptor and estrogen receptor beta.

*John H. Farley, MD*

51G #5088-Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival.

*Julia Dorn, Dr*

51H #5089-Interleukin-6 as a therapeutic target in advanced ovarian cancer.

*Jermaine IG Coward*

52A #5090-Relative conditional survival in 41,476 patients with ovarian cancer.

*Rachel Ware*

52B #5091-Fertility-sparing management with progestin for young women with early-stage endometrial cancer and complex hyperplasia with atypia.

*Jeong-Yeol Park*

52C #5092-Oxaliplatin plus continuous infusion topotecan: An ongoing phase II study for recurrent ovarian cancer-A New York Cancer Consortium study (#N01-CM62204).

*Stacey Stein*

52D #5093-Combination therapy with paclitaxel, carboplatin, and megestrol acetate for advanced-stage and recurrent endometrial carcinoma: A phase II study.

*Kerri S Bevis*

52E #5094-Rapid, durable restoration of malignant ascites-derived antigen presenting cell immunogenicity by toll-like receptor agonists.

*Stephanie Jean*

52F #5095-Vaginal cuff brachytherapy combined with carboplatin and paclitaxel as adjuvant therapy for high-intermediate-risk patients with endometrial carcinoma.

*Lisa M Landrum*

52G #5096-Prognosis and prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma).

*Catherine Uzan*

52H #5097-Sexual activity and functioning in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer.

*Trond Melbye Michelsen*

53A #5098-The efficacy and toxicity of belotecan (CKD-602) combined with platinum in patients with recurrent epithelial ovarian cancer.

*Yong-Man Kim*

53B #5099-Proliferation and lymphangiogenesis markers, and risk of lymph-nodal metastasis in early cervical cancer.

*Stefano Bogliolo*

53F #5100-Prognostic impact of primary surgical outcome on survival after recurrence in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials.

*Sven Mahner*

53G #5101-Relationship between ERCC1 C8092A and Mad1 G558A polymorphism with disease progression, and survival in patients with advanced epithelial ovarian cancer treated with induction chemotherapy with carboplatine paclitaxel (PC).

*LA Herrera Montalvo*

54A #5103-Inactivation of O6-methylguanine-DNA methyltransferase (MGMT) by promoter hypermethylation: A key factor of epithelial ovarian carcinogenesis in specific histologic types.

*Hyun-Jin Roh*

54B #5104-Neoadjuvant chemotherapy in second trimester pregnant patients with cervical cancer: First study on in vivo concentrations of cisplatin in fetal and maternal compartments.

*Simone Marnitz*

54F #5105-Development of a nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer based on the CALYPSO trial.

*Chee Khoon Lee*

54G #5106-What do primary and recurrent ovarian cancer patients (OC) expect from their doctors? Final results of a German survey in 608 patients.

*Gülten Oskay-Özcelik*

54H #5107-A phase I study of the infectivity enhanced CRAd Ad5- $\Delta$ 24RGD for recurrent gynecologic cancer.

*David T Curiel*

55A #5108-A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: HOG GYN-111.

*Daniela Matei*

55B #5109-Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for advanced ovarian cancer.

*Edward J. Tanner*

55C #5110-Prognostic relevance of resection margin distance for loco-regional control in vulvar cancer.

*Linn Woelber*

55D #5111-Predictive value of circulating tumor cells for response to therapy in women with recurrent epithelial ovarian cancer.

*David Kindelberger*

55E #5112-Can we increase response rate (RR) and overall survival (OS) by individualizing chemotherapy in ovarian cancer (OC): The role of a new chemotherapy (CT) induced apoptosis assay.

*Emery Manuel Salom*

55F #5113-Ten-year relative survival for ovarian cancer.

*Lauren Baldwin*

55G #5114-Intraperitoneal chemotherapy: Who, what, when, and how in diverse academic settings.

*Leslie R. Boyd*

55H #5115-A cross sectional study on intestinal and bladder symptoms in gynecologic malignancies.

*K. Pushpalatha*

56A #5116-Efficacy of lower dose of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer resistant to platinum-based therapy.

*Vasiliki Michalaki*

56B #5117-Chemoradiation followed by adjuvant hysterectomy for the treatment of stage IB-2 cervical cancer: 10-year experience.

*Glenn E. Bigsby*

56C #5118-The impact of age on first-line chemotherapy treatment of epithelial ovarian cancer and primary peritoneal carcinoma.

*Emmanuel Larbi*

56D #5119-Clinical significance of selected angiogenesis and lymphangiogenesis modulators and markers in ovarian cancer patients.

*Dagmara Klasa-Mazurkiewicz*

56E #5120-Excision repair cross-complementation group 1 (ERCC1) expression as a predictor for response of neoadjuvant chemotherapy for locally advanced uterine cervix cancer.

*Sang Hoon Jeon*

56F #5121-Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC).

*Ignacio Romero*

56G #5122-The correlation of cone biopsy with findings at radical hysterectomy and the need for adjuvant radiation therapy.

*Todd Patrick Boren*

56H #5123-Cisplatin (C) and ifosfamide (I) chemotherapy with vaginal cuff brachytherapy (VCBT) for treatment of uterine carcinosarcoma.

*Hao Wang, MD, PhD*

**Session Title:** #64: International Collaboration in Clinical Trials: Special Emphasis on Ethics and Regulatory Issues

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** S100a

**Time:** 3:00 PM - 4:15 PM

- Overview of International collaboration in cancer clinical trials  
*Robert Leo Comis, MD*
- European perspective on international collaborative clinical trials  
*Denis A. Lacombe, MD*
- Review NCI symposium on implementation of international collaborative clinical trials in cancer therapies  
*Edward Lloyd Trimble, MD*

**Session Title:** #70: Managing Survivorship in a Community Practice

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E353

**Time:** 3:00 PM - 4:15 PM

- Defining Survivorship, What are the pieces?  
*Barbara A. Parker, MD*
- From the Ground Up. Use of Non-Physician providers in survivorship care.  
*Marina Z. Khitrik-Palchuk, MD*
- Facilitation of a Survivorship Program with the local cancer center  
*Scott D Siegel, PhD*

**Session Title:** #107: Update on Gastrointestinal Noncolorectal Malignancies: What's New since the 2009 ASCO Annual Meeting?

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 3:00 PM - 4:15 PM

- Review of the results of surgical trials including neoadjuvant and adjuvant therapy in upper GI malignancies over the past year

- Hepatobiliary and pancreatic cancers since ASCO 2009: steady steps forward and a long way to go

*Anthony B. El-Khoueiry, MD*

---

**Session Title:** #112: Clinical Management of Hereditary Colorectal Cancer

**Session Type:** Meet the Professor Session

**Date:** Saturday, June 5

**Location:** E451b

**Time:** 3:00 PM - 4:15 PM

- Clinical Management of Hereditary Colorectal Cancer

*Randall Burt, MD*

---

**Session Title:** #122: Health Care Reform: Resetting the Clock

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** E Arie Crown Theater

**Time:** 3:00 PM - 4:15 PM

- Health Care Reform: Resetting the Clock

*Joseph S. Bailes, MD*

- TBD

*J. James Rohack, MD*

---

**Session Title:** #126: Central Nervous System Metastases: From Local to Systemic Therapy

**Session Type:** Clinical Problems in Oncology Session

**Date:** Saturday, June 5

**Location:** E451a

**Time:** 3:00 PM - 4:15 PM

- The integration of surgery and radiation therapy in the management of CNS metastasis in breast cancer

*Matthew G. Ewend, MD*

- Systemic treatment options and opportunities in breast cancer patients with CNS mets

*Nancy U. Lin, MD*

- To Protect and Defend: Novel Treatment and Prevention Options for Patients with Metastatic Breast Cancer and Leptomeningeal Disease

*Michael J. Glantz, MD*

---

**Session Title:** #147: Central Nervous System Tumors

**Session Type:** Oral Abstract Session

**Date:** Saturday, June 5

**Location:** S100b

**Time:** 3:00 PM - 6:00 PM

- Central Nervous System Tumors

*Myrna Rachel Rosenfeld, MD, PhD*

- Central Nervous System Tumors

*John Frederick De Groot, MD*

- #LBA2001-NOA-08 randomized phase III trial of 1 week on/1 week off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem).

*Wolfgang Wick*

- #LBA2002-Glioblastoma (GBM) in Elderly Patients: A Randomized Phase III Trial Comparing Survival in Patients Treated with 6-week Radiotherapy (RT) versus hypofractionated RT over 2 weeks versus Temozolomide single agent Chemotherapy (TMZ) for Glioblastoma (GBM) in the Elderly.

*Annika Malmstrom, Dr*

- Discussion

*Stuart Grossman, MD*

- #2003-Efficacy of tailored treatment for high- and low-risk medulloblastoma in adults: A large prospective phase II trial.

*Alba Ariela Brandes, MD*

- #2004-Everolimus for subependymal giant-cell astrocytomas (SEGAs) in tuberous sclerosis (TS).

*David Neal Franz*

- #2005-Phase II study of preirradiation chemotherapy for CNS germ cell malignancies: Long-term complications.

*Steven I Robinson*

- #2006-Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB).

*Patrick Y. Wen, MD*

- #LBA2007-A prospective, randomized, open label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma.

*Roger Stupp, MD*

- #2008-Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study.

*Timothy Cloughesy, MD*

- Discussion

*Alba Ariela Brandes, MD*

---

**Session Title:** #158: Lung Cancer - Local-Regional and Adjuvant Therapy

**Session Type:** Oral Abstract Session

**Date:** Saturday, June 5

**Location:** E Hall D1

**Time:** 3:00 PM - 5:30 PM

- Lung Cancer - Local-Regional and Adjuvant Therapy

*Joe B. Putnam, MD*

- Lung Cancer - Local-Regional and Adjuvant Therapy

*Katherine Pisters, MD*

- #7000-A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study.

*Kurt G. Tournoy, Prof., Dr.*

- Discussion: Invasive Mediastinal Staging: Necessary and Often Overlooked

*Steven M. Keller, MD*

- #7002^ -Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.

*Tudor-Eliade Ciuleanu, MD, PhD*

- Discussion: Small Cell Lung Carcinoma: New Approaches for an Orphan Illness

*Bonnie S. Glisson, MD*

- #7003-Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer.

*Virginie Westeel*

- #CRA7004-A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).

*Daniel D. Karp*

- #LBA7005-A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor, Gefitinib in Completely Resected Stage IB-IIIA Non Small Cell Lung Cancer (NSCLC), NCIC CTG BR.19

*Glenwood D. Goss*

- Discussion: Evolution of Multimodality Therapy in Early Stage NSCLC

*David Harpole, MD*

- #LBA7007-A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC).

*Panos Fidas, MD*

- Discussion: Novel Therapeutics in Non Small Cell Lung Cancer

*Julie R. Brahmer, MD*

---

**Session Title:** #163: Patient and Survivor Care

**Session Type:** Oral Abstract Session

**Date:** Saturday, June 5

**Location:** E354b

**Time:** 3:00 PM - 6:00 PM

- Patient and Survivor Care

*Barbara A. Murphy, MD*

- Patient and Survivor Care

*Teresa Gilewski, MD*

- #9008-Hepatitis B screening and positivity prior to chemotherapy.

*Jessica P. Hwang, MD, MPH*

- #9009-Prevalence of hepatitis B surface antigen and hepatitis B core antibody in a population initiating immunosuppressive therapy.

*Emmy Ludwig*

- Discussion

*Sandra L. Wong, MD, MS*

- #9010-Yield from risk-based screening in adults treated for cancer in childhood.

*Melissa M. Hudson, MD*

- #9011-Executive functions in aging adult survivors of childhood leukemia.

*Kevin R. Krull*

- #9012-Contrasting effects of religious/spiritual support from religious communities versus medical teams on advanced cancer patient end-of-life care.

*Tracy A. Balboni*

- Discussion

*Betty R. Ferrell, RN, PhD, FAAN*

- #9013-Effect of YOCAS yoga on sleep, fatigue, and quality of life: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors.

*Karen Michelle Mustian*

- #9014-Prevention of pegfilgrastim-induced bone pain (PIP): A URCC CCOP randomized, double-blind, placebo-controlled trial of 510 cancer patients.

*Jeffrey J. Kirshner*

- #9015-A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases.

*Allan Lipton, MD*

- #9016^ -Efficacy and safety of fentanyl pectin nasal spray versus immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain.

*Marie T Fallon*

- Discussion

*Teresa Gilewski, MD*

---

**Session Title:** #269: Pediatric Oncology Award and Lecture

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** S504

**Time:** 3:00 PM - 4:15 PM

- Pediatric Oncology Award and Lecture

*Sharon B. Murphy, MD*

**Session Title:** #223: Novel Therapies for Myeloma

**Session Type:** Clinical Science Symposium

**Date:** Saturday, June 5

**Location:** E354a

**Time:** 4:30 PM - 6:00 PM

- Novel Therapies for Myeloma  
*Asher Alban Akmal Chanan-Khan, MD*
- Novel Therapies for Myeloma  
*Shaji K Kumar, MD*
- #8000-Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).

*Ravi Vij*

- #8001-Phase II study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

*Jesús San-Miguel, MD, PhD*

- Discussion: Novel proteasome and HDAC inhibitors in myeloma

*Paul Gerard Guy Richardson, MD*

- #8002-Pomalidomide plus dexamethasone (Pom/dex) is active in dual lenalidomide/bortezomib refractory multiple myeloma (MM).

*Martha Lacy*

- #8003-Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase 1 study.

*Andrzej J. Jakubowiak, MD, PhD*

- Discussion: New immunomodulatory agents and antibodies in myeloma

*Sagar Lonial, MD*

**Session Title:** #225: Signaling in Pediatric Cancer Comes to the Clinic

**Session Type:** Clinical Science Symposium

**Date:** Saturday, June 5

**Location:** S504

**Time:** 4:30 PM - 5:45 PM

- Signaling in Pediatric Cancer Comes to the Clinic

*Julia Lynne Glade Bender, MD*

- #CRA9501-A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma: A Pediatric Brain Tumor Consortium study (PBTC 25).

*Amar J. Gajjar, MD*

- #9502-A phase I trial of MK-0752 in children with recurrent or refractory CNS malignancies: A Pediatric Brain Tumor Consortium study.

*Maryam Fouladi, MD*

- Discussion: Signaling comes to the clinic

*Richard Greg Gorlick, MD*

---

**Session Title:** #228: PARP Inhibition: DNA Repair as the Target

**Session Type:** Clinical Science Symposium

**Date:** Saturday, June 5

**Location:** E Arie Crown Theater

**Time:** 4:30 PM - 6:00 PM

- PARP Inhibition: DNA Repair as the Target

*Patrick Johnston, MD, PhD*

- PARP Inhibition: DNA Repair as the Target

*Eunice Lee Kwak, MD, PhD*

- Discussion: PARP as a Therapeutic Target

*Alan Hilary Calvert, MD*

- #3000-Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.

*Antoinette R. Tan, MD, MSc*

- #3001-First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.

*Shahneen K. Sandhu*

- #3002-Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.

*Karen A. Gelmon, MD, FRCPC*

- Discussion: State of Development for PARP inhibition

*James H. Doroshow, MD*

**Session Title:** #230: Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets

**Session Type:** Clinical Science Symposium

**Date:** Saturday, June 5

**Location:** S406 (Vista Room)

**Time:** 4:30 PM - 6:00 PM

- Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets

*Kevin B. Kim, MD*

- Oncogenes in Melanoma: Predictive Factors and Therapeutic Targets

*David B. Solit, MD*

- #8500-Clinical outcome and pathologic features associated with NRAS mutation in cutaneous melanoma.

*Bianca Alix Devitt*

- #8501-Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.

*Sapna Pradyuman Patel, MD*

- Discussion

*Neal Rosen, MD, PhD*

- #8502-Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group trial S0438.

*Kim Allyson Margolin, MD*

- #8503-Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

*Richard Kefford*

- Discussion

*Grant A. McArthur, PhD*

**Session Title:** #37: Cutaneous Cancer Syndromes

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** E353

**Time:** 4:45 PM - 6:00 PM

- Advances in Cowden's Syndrome

*Stephen B. Gruber, MD, PhD*

---

**Session Title:** #109: Updates in Hormone Receptor-positive, HER2-positive, and Triple-negative Breast Cancer

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 4:45 PM - 6:00 PM

- What's New in HER2-Positive Breast Cancer?

*Lisa A. Carey, MD*

- What's New in Hormone Receptor-Positive Breast Cancer?

*Mitchell Dowsett, PhD*

- What's New in Triple-Negative Breast Cancer?

*Olufunmilayo I. Olopade, MBBS, FACP*

---

**Session Title:** #111: Aspirin and Non-steroidal Anti-inflammatory Drugs for Colorectal Cancer Prevention

**Session Type:** Meet the Professor Session

**Date:** Saturday, June 5

**Location:** E451b

**Time:** 4:45 PM - 6:00 PM

- Aspirin and Non-steroidal Anti-inflammatory Drugs for Colorectal Cancer Prevention

*John A. Baron, MD*

---

**Session Title:** #127: Complex and Recurrent Gynecologic Cancers: What's an Oncologist to Do?

**Session Type:** Clinical Problems in Oncology Session

**Date:** Saturday, June 5

**Location:** E451a

**Time:** 4:45 PM - 6:00 PM

- Recurrent Germ Cell Tumor of the Ovary

*Seiko Diane Yamada, MD*

- Management of recurrent leiomyosarcoma of the uterus  
*Martee Leigh Hensley, MD, MSc*
  - Management of recurrent low grade serous ovarian carcinoma  
*John H. Farley, MD*
- 

**Session Title:** #246: Genitourinary (Nonprostate) Cancer

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** E Hall D2

**Time:** 5:00 PM - 6:00 PM

- Genitourinary (Nonprostate) Cancer  
*Leonard Joseph Appleman, MD, PhD*
- Genitourinary (Nonprostate) Cancer  
*George Philips, MD, MBBS, MPH*

1 #4520-Association of germline genetic markers in *IL8*, *HIF1A*, *VEGFA*, and *VEGFR2* with treatment response to pazopanib in renal cell carcinoma.

*Howard A Ball*

2 #4521-Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib.

*Karel Eechoute*

3 #4522-Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients.

*Hai T. Tran*

4 #4523-A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.

*Daniel Yick Chin Heng*

5 #4524-The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration.

*Toni K. Choueiri*

6 #4525-Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

*Susan Halabi*

7 #4526-Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma.

*Katherine Margaret Krajewski*

- Discussion: Prediction and prognosis in renal cell carcinoma

*Daniel J. George, MD*

8 #4527-Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure.

*Nizar M. Tannir*

9 #4528^ -A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC).

*Christopher W. Ryan, MD*

10 #4529-Results of a randomized phase II study investigating multipptide vaccination with IMA901 in advanced renal cell carcinoma (RCC).

*Carsten Reinhardt, MD, PhD*

- Discussion: Trial design and drug development in RCC

*Ulka N. Vaishampayan, MD*

12 #4531-Results from SWENOTECA V: A population based protocol for seminomatous testicular cancer.

*Torgrim Tandstad*

13 #4532-Risk-adapted management of stage I seminoma: Results of the third Spanish Germ Cell Cancer Group Study.

*Jorge Aparicio*

14 #4533-Cardiovascular risk in long-term testicular cancer survivors.

*Hege Sagstuen Haugnes*

15 #4534-Total treatment burden in stage I seminoma patients.

*Eric Leung*

16 #4535-Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study.

*Peter W. M. Chung*

17 #4536-Evolution of management of testicular seminoma: Population-based outcomes with decreased utilization of active therapies.

*Craig R. Nichols, MD, FACP*

18 #4537-Risk of secondary malignancy in patients with testicular cancer who have received radiation therapy.

*Daniel Lewinshtein*

19 #4538-Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy.

*Alan Horwich*

- Discussion: Germ cell tumors: is radiation under or over-utilized?

*Mary Gospodarowicz, MD*

20 #4539-Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial.

*David I. Quinn, PhD, FRACP, MBBS*

21 #4540-First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit.

*Joaquim Bellmunt*

22 #4541-Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC).

*Noah M. Hahn*

- Discussion: Is there a role for targeted therapy in advanced urothelial cancer?

*Matthew I. Milowsky, MD*

23 #4542-Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer.

*Lamont J Barlow*

24 #4543-Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle-invasive bladder cancer: A prospective randomized trial.

*Savino Mauro Di Stasi*

- Discussion: New therapies in non-muscle invasive urothelial cancer

*Seth P. Lerner, MD*

**Session Title:** #259: Tumor Biology

**Session Type:** Poster Discussion Session

**Date:** Saturday, June 5

**Location:** S100a

**Time:** 5:00 PM - 6:00 PM

- Tumor Biology

*Charles D. Lopez, MD, PhD*

- Tumor Biology

*Vered Stearns, MD*

1 #10513-Utilization of genomic signatures for chemotherapy response in prospective clinical studies.

*William Barry*

2 #10514-Identification of thymosin beta 15 A (TMSB15A) mRNA expression as a predictor for response to neoadjuvant chemotherapy in patients with operable breast cancer.

*Silvia Darb-Esfahani*

3 #10515-Gene expression in serial biopsies in locally advanced breast cancer patients who failed to respond to neoadjuvant chemotherapy.

*Mark Jesus M Magbanua*

4 #10516-Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay.

*Christian F. Singer*

5 #10517-Correlation of engraftment, mutation status, and response to chemotherapy in primary tumor xenograft models of NSCLC.

*Tom John*

6 #10518-Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis.

*Charlotte Elberling Almasi*

7 #10519-Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies.

*Coen Bernaards*

8 #10520-Value of a serum proteomic signature in the non-invasive evaluation of lung nodules.

*Chad Victor Pecot*

9 #10521-Use of a nanoparticle-based artificial olfactory system, NaNose, to distinguish malignant from benign pulmonary nodules.

*Nir Peled, MD, PhD*

- Discussion

*Gerold Bepler, MD, PhD*

10 #10522-Association of TS and ERCC1 mRNA expressions with overall survival in patients enrolled in CONFIRM 1 + 2.

*Peter P Grimminger*

11 #10523-Prognostic value of the microtubule stability index (MTSI), defined by the quantitative ratio of MAP-tau to stathmin expression, for outcome in breast cancer.

*Maria T. Baquero*

12 #10524-Association of GRP78 gene polymorphism rs391957 with tumor recurrence in gastric and colon cancer patients.

*Pierre Olivier Bohanes, MD*

13 #10525-Correlation of Snail expression and survival in patients with early-stage triple-negative breast cancer (TNBC).

*Sao Jiralerspong, MD, PhD*

14 #10526-MicroRNA deregulation in peripheral nerve sheath tumor progression.

*Nadege Presneau*

15 #10527-Chemobiological screening for identification of molecular targets for thymic epithelial cancers.

*Oscar D. Cano*

16 #10528-Molecular classification of non-small cell lung cancer using a four protein quantitative assay.

*Valsamo K. Anagnostou, MD*

17 #10529-KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy.

*Kathleen D Danenberg*

18 #10530-Prognostic implications of mutations in the epidermal growth factor receptor (*EGFR*) and *KRAS* among never-smokers with adenocarcinoma of the lung.

*Paul K. Paik*

- Discussion

*David Paul Carbone, MD, PhD*

19 #10531-Comprehensive analysis of expression patterns of insulin-like growth factor and Src pathway in patients with non-small cell lung cancer: Two large, independent series of tissue microarray.

*Jin-Soo Kim, MD*

20 #10532-Immunohistochemical screening of ALK lung cancer with biopsy specimens of advanced lung cancer.

*Keita Kudo*

21 #10533-ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC).

*Marileila Varella-Garcia*

22 #10534-A Japanese, nationwide network for the diagnosis of EML4-ALK-positive lung cancer: A joint study of ALCAS and NEJ004.

*Manabu Soda*

23 #10535-A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue.

*Peter V Danenberg*

24 #10536-Frequencies of ALK and ROS in NSCLC FFPE tumor samples utilizing a highly specific immunohistochemistry-based assay and FISH analysis.

*Victoria Rimkunas*

25 #10537-ALK chromosomal alterations in colon cancer patients.

*Clara Montagut*

- Discussion

*Robert Arthur Kratzke, MD*